# ChatGPT for assessing risk of bias of randomized trials using the RoB 2.0 tool: A methods study

Dena Zeraatkar

*Departments of Anesthesia and Health Research Methods, Evidence, and Impact*

*McMaster University, Hamilton, ON*

*zeraatd@mcmaster.ca*

Table of Contents

[ChatGPT for assessing risk of bias of randomized trials using the RoB 2.0 tool: A methods study 1](#_Toc150185219)

[Supplement 1: ChatGPT prompts for generating risk of bias judgments 3](#_Toc150185220)

[Chat GPT Minimal Prompt 3](#_Toc150185221)

[Chat GPT Maximal Prompt 4](#_Toc150185222)

[Chat GPT Optimized Prompt 6](#_Toc150185223)

[Supplement 2: List of excluded reviews and reasons for exclusion 7](#_Toc150185224)

[Supplement 3: Weighted kappa values for trials addressing pharmacologic treatments 46](#_Toc150185225)

[Supplement 4: Weighted kappa values for trials from reviews that assessed the risk of bias of assignment to the intervention 47](#_Toc150185226)

[Supplement 5: Weighted kappa values for outcomes rated as definitely objective 48](#_Toc150185227)

[Supplement 6: Weighted kappa values for outcomes rated as definitely subjective 49](#_Toc150185228)

[Supplement 7: Weighted kappa values for outcomes rated as definitely objective or as probably objective 50](#_Toc150185229)

[Supplement 8: Weighted kappa values for outcomes rated as definitely subjective or as probably subjective 51](#_Toc150185230)

[Supplement 9: Weighted kappa values for continuous outcomes 52](#_Toc150185231)

# Supplement 1: ChatGPT prompts for generating risk of bias judgments

A key component in the use of ChatGPT is the design of the text used to instruct the model (called ‘prompts’) to generate an answer. We anticipated that ChatGPT’s risk of bias judgements may be dependent on the nature of the prompts that it is provided. To study how different prompts may influence risk of bias judgements, we iteratively designed three different prompts: a minimal prompt including limited instructions, a maximal prompt with extensive instructions, and an optimized prompt that was developed to include sufficient information to yield the best risk of bias judgements. These prompts are shown below.

All prompts asked ChatGPT to judge risk of bias for all RoB 2.0 domains (bias due to randomization, deviation from intended intervention, missing outcome data, measurement of outcome, and selective reporting) as low risk of bias, some concerns, or high risk of bias.

The RoB 2.0 tool is accompanied by a guidance document that describes the tool and offers guidance on its implementation. All three prompts included the RoB 2.0 full guidance document (riskofbias.info), which were fed to ChatGPT using the AskYourPDF ChatGPT plugin that allows ChatGPT to read and query pdf documents. All prompts also included a PDF copy of the trial publication, a PDF copy of the trial registration or protocol (if one was available), and specified the outcome of interest for which risk of bias assessment was being performed. PDF documents that were included in the prompt are represented by ‘doc\_id’, which are generated by the AskYourPDF ChatGPT plugin.

The RoB 2.0 tool offers two options for assessing the risk of bias due to deviations of the intended intervention: one for the effect assignment to the intervention and the other for the effect of adhering to the intervention. Cochrane systematic reviews typically report whether they assess risk of bias for the effect of assignment or adherence to the intervention in the risk of bias subsection. Our ChatGPT prompts also specified whether to assess risk of bias for the effect of assignment or adherence to the intervention, depending on the option selected by the Cochrane review authors. For systematic reviews that failed to specify whether they assessed risk of bias for the effect of being assigned to the intervention or adherence to the intervention, we assumed they assessed risk of bias for assignment to the intervention.

We piloted the prompts using 15 trials drawn from systematic reviews previously performed by our own team and refined the prompts by iterative discussion and input by the co-authors.

Highlighted sections of the prompts are modified according to the trial or outcome for which risk of bias is being assessed.

## Chat GPT Minimal Prompt

You will assess the risk of bias of a randomized trial using the RoB 2.0 tool. The full guidance for the RoB 2.0 tool is here: doc\_id: cb87d5e2-5f77-4d7b-b3bd-456368bc7129

Use the RoB 2.0 guidance to provide a judgement of risk of bias of the following trial for the outcome complete cessation of prescription fills: doc\_id: 4596e66d-aaa4-452a-a4aa-01ca2533c291

The RoB 2.0 tool presents two options for assessing the risk of bias of bias due to deviations of the intended intervention. The first option assesses the risk of bias for the effect of assignment to the interventions at baseline. The second option assesses risk of bias for the effect of adhering to intervention. Assess the risk of bias due to deviations of the intended intervention considering the effect of assignment to the interventions at baseline rather than the effect of adhering to the intervention.

To assess risk of bias due to selective reporting, you may use information contained in the trial registration: doc\_id: 4dab5cab-2b44-42f8-8559-2dd9073b18b5

The format and order of your final response would be as follows:

1. bias due to randomization
	1. Judgement: Provide rating of risk of bias as either low risk of bias, some concerns or high risk of bias.
	2. Rationale: Reasoning, potentially quotes from the trial publication, to support your judgement.
2. deviations from intended intervention
	1. Judgement: Provide rating of risk of bias as either low risk of bias, some concerns or high risk of bias.
	2. Rationale: Reasoning, potentially quotes from the trial publication, to support your judgement.
3. missing outcome data
	1. Judgement: Provide rating of risk of bias as either low risk of bias, some concerns or high risk of bias.
	2. Rationale: Reasoning, potentially quotes from the trial publication, to support your judgement.
4. measurement of the outcome
	1. Judgement: Provide rating of risk of bias as either low risk of bias, some concerns or high risk of bias.
	2. Rationale: Reasoning, potentially quotes from the trial publication, to support your judgement.
5. selective reporting
	1. Judgement: Provide rating of risk of bias as either low risk of bias, some concerns or high risk of bias.
	2. Rationale: Reasoning, potentially quotes from the trial publication, to support your judgement.

## Chat GPT Maximal Prompt

 You will assess the risk of bias of a randomized trial using the RoB 2.0 tool. The full guidance for the RoB 2.0 tool is here: doc\_id: cb87d5e2-5f77-4d7b-b3bd-456368bc7129

Use the RoB 2.0 guidance to provide a judgement of risk of bias of the following trial for the outcome complete cessation of prescription fills: doc\_id: 4596e66d-aaa4-452a-a4aa-01ca2533c291

The RoB 2.0 tool presents two options for assessing the risk of bias of bias due to deviations of the intended intervention. The first option assesses the risk of bias for the effect of assignment to the interventions at baseline. The second option assesses risk of bias for the effect of adhering to intervention. Assess the risk of bias due to deviations of the intended intervention considering the effect of assignment to the interventions at baseline rather than the effect of adhering to the intervention.

To assess risk of bias due to selective reporting, you may use information contained in the trial registration: doc\_id: 4dab5cab-2b44-42f8-8559-2dd9073b18b5

Consistent with RoB 2.0 guidance, to make judgements about bias due to randomization, consider:

1. Was allocation sequence concealed?
2. Was the allocation sequence random?
3. Do baseline imbalances suggest a problem with the randomization process?

To make judgements about risk of bias due to randomization, consider:

1. Were participants and personnel aware of the intervention?
2. Did deviations arise because of the trial context?
3. Did deviations affect the outcome?
4. Were deviations (e.g., cointerventions) likely balanced between groups?

To make judgements about bias due to missing outcome data, consider:

1. Was there outcome data available for all or most participants?
2. Is there evidence that the result is not biased due to missing data?
3. Could missingness depend on the true value of the outcome?

To make judgements about measurement of the outcome, consider:

1. Was the method for measuring the outcome appropriate?
2. Did the method for measuring the outcome differ between trial arms?
3. Were outcome assessors aware of the intervention?
4. Could outcome assessment be influenced by knowledge of the intervention?

To make judgements about selective reporting, consider:

1. Were results selected from multiple outcome measurements or analyses of the data?

Was the trial analyzed according to a prespecified statistical analysis plan?

The format and order of your final response would be as follows:

1. bias due to randomization
	1. Judgement: Provide rating of risk of bias as either low risk of bias, some concerns or high risk of bias.
	2. Rationale: Reasoning, potentially quotes from the trial publication, to support your judgement.
2. deviations from intended intervention
	1. Judgement: Provide rating of risk of bias as either low risk of bias, some concerns or high risk of bias.
	2. Rationale: Reasoning, potentially quotes from the trial publication, to support your judgement.
3. missing outcome data
	1. Judgement: Provide rating of risk of bias as either low risk of bias, some concerns or high risk of bias.
	2. Rationale: Reasoning, potentially quotes from the trial publication, to support your judgement.
4. measurement of the outcome
	1. Judgement: Provide rating of risk of bias as either low risk of bias, some concerns or high risk of bias.
	2. Rationale: Reasoning, potentially quotes from the trial publication, to support your judgement.
5. selective reporting
	1. Judgement: Provide rating of risk of bias as either low risk of bias, some concerns or high risk of bias.
	2. Rationale: Reasoning, potentially quotes from the trial publication, to support your judgement.

## Chat GPT Optimized Prompt

You will assess the risk of bias of a randomized trial using the RoB 2.0 tool. The full guidance for the RoB 2.0 tool is here: doc\_id: cb87d5e2-5f77-4d7b-b3bd-456368bc7129

Use the RoB 2.0 guidance to provide a judgement of risk of bias of the following trial for the outcome complete cessation of prescription fills: doc\_id: 4596e66d-aaa4-452a-a4aa-01ca2533c291

The RoB 2.0 tool presents two options for assessing the risk of bias of bias due to deviations of the intended intervention. The first option assesses the risk of bias for the effect of assignment to the interventions at baseline. The second option assesses risk of bias for the effect of adhering to intervention. Assess the risk of bias due to deviations of the intended intervention considering the effect of assignment to the interventions at baseline rather than the effect of adhering to the intervention.

To assess risk of bias due to selective reporting, you may use information contained in the trial registration: doc\_id: 4dab5cab-2b44-42f8-8559-2dd9073b18b5

The format and order of your final response would be as follows:

1. bias due to randomization
	1. Judgement: Provide rating of risk of bias as either low risk of bias, some concerns or high risk of bias.
	2. Rationale: Reasoning, potentially quotes from the trial publication, to support your judgement.
2. deviations from intended intervention
	1. Judgement: Provide rating of risk of bias as either low risk of bias, some concerns or high risk of bias.
	2. Rationale: Reasoning, potentially quotes from the trial publication, to support your judgement.
3. missing outcome data
	1. Judgement: Provide rating of risk of bias as either low risk of bias, some concerns or high risk of bias.
	2. Rationale: Reasoning, potentially quotes from the trial publication, to support your judgement.
4. measurement of the outcome
	1. Judgement: Provide rating of risk of bias as either low risk of bias, some concerns or high risk of bias.
	2. Rationale: Reasoning, potentially quotes from the trial publication, to support your judgement.
5. selective reporting
	1. Judgement: Provide rating of risk of bias as either low risk of bias, some concerns or high risk of bias.
	2. Rationale: Reasoning, potentially quotes from the trial publication, to support your judgement.

# Supplement 2: List of included review

|  |  |  |
| --- | --- | --- |
| DOI | Author | Year |
| 10.1002/14651858.CD012940.pub3 | Abiramalatha  | 2023 |
| 10.1002/14651858.CD012937.pub3 | Abiramalatha  | 2023 |
| 10.1002/14651858.CD013778 | Ammous | 2023 |
| 10.1002/14651858.CD004128.pub5 | Arrich | 2023 |
| 10.1002/14651858.CD014676.pub2 | Bai | 2023 |
| 10.1002/14651858.CD001211.pub4 | Chen | 2023 |
| 10.1002/14651858.CD015078 | Fischer | 2023 |
| 10.1002/14651858.CD013398.pub4 | Fox | 2022 |
| 10.1002/14651858.CD001423.pub4 | Franco | 2023 |
| 10.1002/14651858.CD015031.pub2 | Ghoraba | 2023 |
| 10.1002/14651858.CD013881.pub2 | Ghosn | 2023 |
| 10.1002/14651858.CD015477 | Grana | 2022 |
| 10.1002/14651858.CD005955.pub3 | Hartley | 2022 |
| 10.1002/14651858.CD014890.pub2 | Hjetland | 2023 |
| 10.1002/14651858.CD013600.pub5 | Iannizzi | 2023 |
| 10.1002/14651858.CD007524.pub5 | Kew | 2022 |
| 10.1002/14651858.CD015167.pub2 | Kimber | 2023 |
| 10.1002/14651858.CD015209 | Kramer  | 2022 |
| 10.1002/14651858.CD014758.pub2 | Lawrenson | 2023 |
| 10.1002/14651858.CD015070.pub2 | Liu | 2022 |
| 10.1002/14651858.CD014831.pub2 | Mayhew | 2022 |
| 10.1002/14651858.CD004917.pub4 | Mehner | 2023 |
| 10.1002/14651858.CD013871.pub2 | Minkoff | 2023 |
| 10.1002/14651858.CD015391 | Nyirenda  | 2022 |
| 10.1002/14651858.CD013799.pub2 | Oba | 2022 |
| 10.1002/14651858.CD015116.pub2 | Ong | 2023 |
| 10.1002/14651858.CD013820.pub2 | Purcell | 2023 |
| 10.1002/14651858.CD013744 | Ramanadhan | 2023 |
| 10.1002/14651858.CD014384.pub2 | Rodolico | 2022 |
| 10.1002/14651858.CD013619.pub2 | Rubin  | 2023 |
| 10.1002/14651858.CD011006.pub4 | Vita | 2023 |
| 10.1002/14651858.CD014963.pub2 | Wagner | 2022 |
| 10.1002/14651858.CD013865.pub2 | Watanabe | 2022 |
| 10.1002/14651858.CD014909.pub2 | Willis | 2023 |

# Supplement 3: List of excluded reviews and reasons for exclusion

|  |  |  |  |
| --- | --- | --- | --- |
| Authors | Title | Year | Reason for exclusion |
|  |
|  |
| Malik, AK, Amer, AO, Tingle, SJ, Thompson, ER, White, SA, Manas, DM, Wilson, C | Fibrin‐based haemostatic agents for reducing blood loss in adult liver resection | 2023 | Does not use RoB 2.0 |  |
| Karkou, V, Aithal, S, Richards, M, Hiley, E, Meekums, B | Dance movement therapy for dementia | 2023 | Does not use RoB 2.0 |  |
| Mohamed, ZUmer, Varghese, CTitus, Sudhakar, A, Kumar, L, Gopalakrishnan, U, Balakrishnan, D, Narayanamenon, R, Sudhindran, S | Prostaglandins for adult liver transplanted recipients | 2023 | Does not use RoB 2.0 |  |
| Clezar, CNB, Flumignan, CDQ, Cassola, N, Nakano, LCU, Trevisani, VFM, Flumignan, RLG | Pharmacological interventions for asymptomatic carotid stenosis | 2023 | Does not use RoB 2.0 |  |
| Roy NB, Fortin PM, Bull KR, Doree C, Trivella M, Hopewell S, Estcourt LJ | Interventions for chronic kidney disease in people with sickle cell disease | 2023 | Does not use RoB 2.0 |  |
| White, LD, Vlok, RA, Thang, CYC, Tian, DH, Melhuish, TM | Oxygenation during the apnoeic phase preceding intubation in adults in prehospital, emergency department, intensive care and operating theatre environments | 2023 | Does not use RoB 2.0 |  |
| Zhu, P, Dong, S, Sun, P, Belgaumkar, AP, Sun, Y, Cheng, X, Zheng, Q, Li, T | Expanded polytetrafluoroethylene (ePTFE)-covered stents versus bare stents for transjugular intrahepatic portosystemic shunt in people with liver cirrhosis | 2023 | Does not use RoB 2.0 |  |
| Bellon, F, Sola, I, Gimenez-Perez, G, Hernandez, M, Metzendorf, M-I, Rubinat, E, Mauricio, D | Perioperative glycaemic control for people with diabetes undergoing surgery | 2023 | Does not use RoB 2.0 |  |
| Setthawong, V, Srisubat, A, Potisat, S, Lojanapiwat, B, Pattanittum, P | Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal surgery (RIRS) for kidney stones | 2023 | Does not use RoB 2.0 |  |
| Schroll, JB, Black, AY, Farquhar, C, Chen, I | Combined oral contraceptive pill for primary dysmenorrhoea | 2023 | Does not use RoB 2.0 |  |
| Möhler R, Richter T, Köpke S, Meyer G | Interventions for preventing and reducing the use of physical restraints for older people in all long-term care settings | 2023 | Does not use RoB 2.0 |  |
| Wilhelm, K, Hein, S, Kunath, F, Schoenthaler, M, Schmidt, S | Totally tubeless, tubeless, and tubed percutaneous nephrolithotomy for treating kidney stones | 2023 | Does not use RoB 2.0 |  |
| Ralovska, S, Koychev, I, Marinov, P, Furukawa, TA, Mulsant, B, Cipriani, A | Brexpiprazole versus placebo or other antidepressive agents for treating depression | 2023 | Does not use RoB 2.0 |  |
| Lemyre, B, Deguise, M-O, Benson, P, Kirpalani, H, De Paoli, AG, Davis, PG | Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation | 2023 | Does not use RoB 2.0 |  |
| Cai, PL, Hitchman, LH, Mohamed, AH, Smith, GE, Chetter, I, Carradice, D | Endovenous ablation for venous leg ulcers | 2023 | Does not use RoB 2.0 |  |
| Roehrs, H, Stocco, JGD, Pott, F, Blanc, G, Meier, MJ, Dias, FAL | Dressings and topical agents containing hyaluronic acid for chronic wound healing | 2023 | Does not use RoB 2.0 |  |
| Fox, T, Hunt, BJ, Ariens, RAS, Towers, GJ, Lever, R, Garner, P, Kuehn, R | Plasmapheresis to remove amyloid fibrin(ogen) particles for treating the post-COVID-19 condition | 2023 | Does not include any eligible trials |  |
| Maher, C, Yeung, E, Haya, N, Christmann-Schmid, C, Mowat, A, Chen, Z, Baessler, K | Surgery for women with apical vaginal prolapse | 2023 | Does not use RoB 2.0 |  |
| Sharif, S, Meader, N, Oddie, SJ, Rojas-Reyes, MX., McGuire, W | Probiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants | 2023 | Does not use RoB 2.0 |  |
| Ballesteros J, Moreno-Calvete MC, Santos-Zorrozúa B, González-Fraile E | Cognitive behavioural therapy plus standard care versus standard care for persistent aggressive behaviour or agitation in people with schizophrenia | 2023 | Does not use RoB 2.0 |  |
| Sarpe, AKP, Flumignan, CDQ, Nakano, LCU, Trevisani, VFM, Lopes, RD, Guedes Neto, HJ, Flumignan, RLG | Duplex ultrasound for surveillance of lower limb revascularisation | 2023 | Does not use RoB 2.0 |  |
| Franciosi JP, Gordon M, Sinopoulou V, Dellon ES, Gupta SK, Reed CC, Gutiérrez-Junquera C, Venkatesh RD, Erwin EA, Egiz A, Elleithy A, Mougey EB | Medical treatment of eosinophilic esophagitis | 2023 | Does not use RoB 2.0 |  |
| Zacharias, HD, Kamel, F, Tan, J, Kimer, N, Gluud, LL, Morgan, MY | Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis | 2023 | Does not use RoB 2.0 |  |
| Cooper, TE, Teng, C, Tunnicliffe, DJ, Cashmore, BA, Strippoli, GFM | Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease | 2023 | Does not use RoB 2.0 |  |
| Moloi, H, Daniels, K, Brooke-Sumner, C, Cooper, S, Odendaal, WA, Thorne, M, Akama, E, Leon, N | Healthcare workers' perceptions and experiences of primary healthcare integration: a scoping review of qualitative evidence | 2023 | Does not use RoB 2.0 |  |
| Lemyre, B, Deguise, M-O, Benson, P, Kirpalani, H, Ekhaguere, OA, Davis, PG | Early nasal intermittent positive pressure ventilation (NIPPV) versus early nasal continuous positive airway pressure (NCPAP) for preterm infants | 2023 | Does not use RoB 2.0 |  |
| Laloo, R, Dewi, M, Gwilym, BL, Richards, OJ, McLain, AD, Bosanquet, D | Tourniquet use for people with peripheral arterial disease undergoing major lower limb amputations | 2023 | Does not use RoB 2.0 |  |
| Jones, M, Moffatt, F, Harvey, A, Ryan, JM | Interventions for improving adherence to airway clearance treatment and exercise in people with cystic fibrosis | 2023 | Does not use RoB 2.0 |  |
| Ho, JJ, Zakarija-Grkovic, I, Lok, JW, Lim, E, Subramaniam, P, Leong, JJ | Continuous positive airway pressure (CPAP) for apnoea of prematurity | 2023 | Does not use RoB 2.0 |  |
| Xiong, T, Fraison, E, Kolibianaki, E, Costello, MF, Venetis, C, Kostova, EB | Statins for women with polycystic ovary syndrome not actively trying to conceive | 2023 | Does not use RoB 2.0 |  |
| Perinpanathan, T, Maiya, S, van Velthoven, MHHMMT, Nguyen, AT, Free, C, Smith, C | Mobile phone-based interventions for improving contraception use | 2023 | Does not use RoB 2.0 |  |
| Hui, S, Sinopoulou, V, Gordon, M, Aali, G, Krishna, A, Ding, NS, Boyapati, RK | Vedolizumab for induction and maintenance of remission in Crohn's disease | 2023 | Does not use RoB 2.0 |  |
| Rosenberg, JE, Ergun, O, Hwang, EC, Risk, MC, Jung, JH, Edwards, ME, Blair, Y, Dahm, P | Non-surgical therapies for Peyronie's disease | 2023 | Does not use RoB 2.0 |  |
| Goodfellow, M, Thompson, ER, Tingle, SJ, Wilson, C | Early versus late removal of urinary catheter after kidney transplantation | 2023 | Does not use RoB 2.0 |  |
| Nascimento Leite, M, Kamper, SJ, O'Connell, NE, Michaleff, ZA, Fisher, E, Viana Silva, P, Williams, CM, Yamato, TP | Physical activity and education about physical activity for chronic musculoskeletal pain in children and adolescents | 2023 | Does not use RoB 2.0 |  |
| Reinhart, M, Puil, L, Salzwedel, DM, Wright, JM | First-line diuretics versus other classes of antihypertensive drugs for hypertension | 2023 | Does not use RoB 2.0 |  |
| Lee, SW, Chen, WS, Sellappans, R, Md.Sharif, SB, Metzendorf, M-I, Lai, NM | Interventions for people with type 2 diabetes mellitus fasting during Ramadan | 2023 | Does not use RoB 2.0 |  |
| Sbidian, E, Chaimani, A, Guelimi, R, Garcia-Doval, I, Hua, C, Hughes, C, Naldi, L, Kinberger, M, Afach, S, Le Cleach, L | Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis | 2023 | Does not use RoB 2.0 |  |
| Sasongko, TH, Kademane, K, Chai Soon Hou, S, Jocelyn, TX, Zabidi-Hussin, Z | Rapamycin and rapalogs for tuberous sclerosis complex | 2023 | Does not use RoB 2.0 |  |
| Shaw, V, Yu, A, Parsons, M, Olsen, T, Walker, C | Acute assessment services for patient flow assistance in hospital emergency departments | 2023 | Does not use RoB 2.0 |  |
| Taithongchai, A, Johnson, EE, Ismail, SI, Barron-Millar, E, Kernohan, A, Thakar, R | Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women | 2023 | Does not use RoB 2.0 |  |
| Pels, A, Ganzevoort, W, Kenny, LC, Baker, PN, von Dadelszen, P, Gluud, C, Kariya, CT, Leemhuis, AG, Groom, KM, Sharp, AN, Magee, LA, Jakobsen, JC, Mol, BWJ, Papageorghiou, AT | Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy | 2023 | Does not use RoB 2.0 |  |
| Gijtenbeek, RGP, de Jong, K, Venmans, BJW, van Vollenhoven, FHM, Ten Brinke, A, Van der Wekken, AJ, van Geffen, WH | Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status | 2023 | Does not use RoB 2.0 |  |
| Newhouse, R, Nelissen, E, El-Shakankery, KH, Rogozi≈Ñska, E, Bain, E, Veiga, S, Morrison, J | Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer | 2023 | Does not use RoB 2.0 |  |
| Allida, SM, Hsieh, C-F, Cox, KL, Patel, K, Rouncefield-Swales, A, Lightbody, CE, House, A, Hackett, ML | Pharmacological, non-invasive brain stimulation and psychological interventions, and their combination, for treating depression after stroke | 2023 | Does not use RoB 2.0 |  |
| Kudlicka, A, Martyr, A, Bahar-Fuchs, A, Sabates, J, Woods, B, Clare, L | Cognitive rehabilitation for people with mild to moderate dementia | 2023 | Does not use RoB 2.0 |  |
| Livingstone-Banks, J, Fanshawe, TR, Thomas, KH, Theodoulou, A, Hajizadeh, A, Hartman, L, Lindson, N | Nicotine receptor partial agonists for smoking cessation | 2023 | Does not use RoB 2.0 |  |
| Hanna, M, Shah, R, Marquez, L, Barzegar, R, Gordon, A, Pammi, M | Infant isolation and cohorting for preventing or reducing transmission of healthcare-associated infections in neonatal units | 2023 | Does not use RoB 2.0 |  |
| Virgili, G, Curran, K, Lucenteforte, E, Peto, T, Parravano, M | Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis | 2023 | Does not use RoB 2.0 |  |
| Narayan, A, Evans, JR, O'Brart, D, Bunce, C, Gore, DM, Day, AC | Laser-assisted cataract surgery versus standard ultrasound phacoemulsification cataract surgery | 2023 | Does not use RoB 2.0 |  |
| Ma, S, Song, SJ | Oral contraceptives containing drospirenone for premenstrual syndrome | 2023 | Does not use RoB 2.0 |  |
| Kinoshita, M, Olsson, E, Borys, F, Bruschettini, M | Opioids for procedural pain in neonates | 2023 | Does not use RoB 2.0 |  |
| Chekima, K, Yan, SW, Lee, SWen Huey, Wong, TZe, Noor, MI, Ooi, YBH, Metzendorf, M-I, Lai, NM | Low glycaemic index or low glycaemic load diets for people with overweight or obesity | 2023 | Does not use RoB 2.0 |  |
| Chakupurakal, G, Freudenberger, P, Skoetz, N, Ahr, H, Theurich, S | Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults | 2023 | Does not use RoB 2.0 |  |
| Buchan, EJ, Haywood, A, Syrmis, W, Good, P | Medically assisted hydration for adults receiving palliative care | 2023 | Does not use RoB 2.0 |  |
| Veth, VB, van de Kar, MMA, Duffy, JMN, van Wely, M, Mijatovic, V, Maas, JWM | Gonadotropin-releasing hormone analogues for endometriosis | 2023 | Does not use RoB 2.0 |  |
| El-Angbawi, A, McIntyre, G, Fleming, PS, Bearn, D | Non-surgical adjunctive interventions for accelerating tooth movement in patients undergoing orthodontic treatment | 2023 | Does not use RoB 2.0 |  |
| Greene, Z, O'Donnell, CPF, Walshe, M | Oral stimulation for promoting oral feeding in preterm infants | 2023 | Does not use RoB 2.0 |  |
| Pammi, M, Haque, KN | Pentoxifylline for treatment of sepsis and necrotising enterocolitis in neonates | 2023 | Does not use RoB 2.0 |  |
| Theodoulou, A, Chepkin, SC, Ye, W, Fanshawe, TR, Bullen, C, Hartmann-Boyce, J, Livingstone-Banks, J, Hajizadeh, A, Lindson, N | Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation | 2023 | Does not use RoB 2.0 |  |
| Lai, M, Zhou, S, He, S, Cheng, Y, Cheng, N, Deng, Y, Ding, X | Fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery | 2023 | Does not use RoB 2.0 |  |
| Verma, R, Chandarana, M, Barrett, J, Anandadas, C, Sundara Rajan, S | Post-mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes | 2023 | Does not use RoB 2.0 |  |
| Báez G, Vargas C, Arancibia M, Papuzinski C, Franco JV | Non-Chinese herbal medicines for functional dyspepsia | 2023 | Does not use RoB 2.0 |  |
| Araujo, DN, Ribeiro, CTD, Maciel, ACC, Bruno, SS, Fregonezi, GAF, Dias, FAL | Physical exercise for the treatment of non-ulcerated chronic venous insufficiency | 2023 | Does not use RoB 2.0 |  |
| Wark, P, McDonald, VM, Smith, S | Nebulised hypertonic saline for cystic fibrosis | 2023 | Does not use RoB 2.0 |  |
| Tzoumas, N, Riding, G, Williams, MA, Steel, DHW | Complement inhibitors for age-related macular degeneration | 2023 | Does not use RoB 2.0 |  |
| Pillai Riddell, RR, Bucsea, O, Shiff, I, Chow, C, Gennis, HG, Badovinac, S, DiLorenzo-Klas, M, Racine, NM, Ahola Kohut, S, Lisi, D, Turcotte, K, Stevens, B, Uman, LS | Non-pharmacological management of infant and young child procedural pain | 2023 | Does not use RoB 2.0 |  |
| Motamedi, MAK, Mak, NT, Brown, CJ, Raval, MJ, Karimuddin, AA, Giustini, D, Phang, PTerry | Local versus radical surgery for early rectal cancer with or without neoadjuvant or adjuvant therapy | 2023 | Does not use RoB 2.0 |  |
| Kataoka, SY, Lois, N, Kawano, S, Kataoka, Y, Inoue, K, Watanabe, N | Fenofibrate for diabetic retinopathy | 2023 | Does not use RoB 2.0 |  |
| Yoong, SL, Lum, M, Wolfenden, L, Jackson, J, Barnes, C, Hall, AE, McCrabb, S, Pearson, N, Lane, C, Jones, JZ, Dinour, L, McDonnell, T, Booth, D, Grady, A | Healthy eating interventions delivered in early childhood education and care settings for improving the diet of children aged six months to six years | 2023 | Does not use RoB 2.0 |  |
| Ugwu, EO, Eleje, GU, Ugwu, AO, Nwagha, UI, Ikechebelu, JI, Umeh, UA, Okafor, HU | Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus | 2023 | Does not use RoB 2.0 |  |
| Ferraro, MC, Cashin, AG, Wand, BM, Smart, KM, Berryman, C, Marston, L, Moseley, GL, McAuley, JH, O'Connell, NE | Interventions for treating pain and disability in adults with complex regional pain syndrome- an overview of systematic reviews | 2023 | Does not use RoB 2.0 |  |
| Fulone, I, Cadogan, C, Barberato-Filho, S, Bergamaschi, CC, Mazzei, LG, Lopes, LP, Silva, MT, Lopes, LC | Pharmaceutical policies: effects of policies regulating drug marketing | 2023 | Does not use RoB 2.0 |  |
| Lewis, SR, Pritchard, MW, Estcourt, LJ, Stanworth, SJ, Griffin, XL | Interventions for reducing red blood cell transfusion in adults undergoing hip fracture surgery: an overview of systematic reviews | 2023 | Does not use RoB 2.0 |  |
| Asfar, T, Livingstone-Banks, J, Ward, KD, Eissenberg, T, Oluwole, O, Bursac, Z, Ghaddar, T, Maziak, W | Interventions for waterpipe smoking cessation | 2023 | Does not use RoB 2.0 |  |
| Colli, A, Fraquelli, M, Prati, D, Casazza, G | Granulocyte colony-stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease | 2023 | Does not use RoB 2.0 |  |
| Kuti, BP, Ogunlesi, TA, Oduwole, O, Oringanje, CCMO, Udoh, EE, Bello, S, Horn, D, Meremikwu, MM | Hand hygiene for the prevention of infections in neonates | 2023 | Does not use RoB 2.0 |  |
| Häuser W, Welsch P, Radbruch L, Fisher E, Bell RF, Moore RA | Cannabis-based medicines and medical cannabis for adults with cancer pain | 2023 | Does not use RoB 2.0 |  |
| Wu, H, Jiang, J, Cao, X, Wang, J, Li, C | Magnetic seizure therapy for people with schizophrenia | 2023 | Does not use RoB 2.0 |  |
| Riera, R, Torloni, MR, Martimbianco, ALC, Pacheco, RL | Alemtuzumab for multiple sclerosis | 2023 | Does not use RoB 2.0 |  |
| McGee, RG, Webster, AC, Lewis, SR, Welsford, M | Interventions for the symptoms and signs resulting from jellyfish stings | 2023 | Does not use RoB 2.0 |  |
| Fukuda, N, Horita, N, Kaneko, A, Goto, A, Kaneko, T, Ota, E, Kew, KM | Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease | 2023 | Does not use RoB 2.0 |  |
| Gibbs VN, Geneen LJ, Champaneria R, Raval P, Dorée C, Brunskill SJ, Novak A, Palmer AJ, Estcourt LJ | Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint replacement for hip, pelvic and long bone fractures | 2023 | Does not use RoB 2.0 |  |
| B Aledi, L, Flumignan, CDQ, Trevisani, VFM, Miranda Jr, F | Interventions for motor rehabilitation in people with transtibial amputation due to peripheral arterial disease or diabetes | 2023 | Does not use RoB 2.0 |  |
| Tan, HS, Zeng, Y, Qi, Y, Sultana, R, Tan, CW, Sia, AT, Sng, BL, Siddiqui, FJ | Automated mandatory bolus versus basal infusion for maintenance of epidural analgesia in labour | 2023 | Does not use RoB 2.0 |  |
| Caro, P, Turner, W, Caldwell, DM, Macdonald, G | Comparative effectiveness of psychological interventions for treating the psychological consequences of sexual abuse in children and adolescents: a network meta-analysis | 2023 | Does not use RoB 2.0 |  |
| Langton Hewer, SC, Smith, S, Rowbotham, NJ, Yule, A, Smyth, AR | Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis | 2023 | Does not use RoB 2.0 |  |
| Mohanannair Geethadevi, G, Quinn, TJ, George, J, Anstey, KJ, Bell, JS, Sarwar, MR, Cross, AJ | Multi-domain prognostic models used in middle-aged adults without known cognitive impairment for predicting subsequent dementia | 2023 | Does not use RoB 2.0 |  |
| Sharif, S, Oddie, SJ, Heath, PT, McGuire, W | Prebiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants | 2023 | Does not use RoB 2.0 |  |
| Ure, A, Cox, GR, Haslam, R, Williams, K | Acetylcholinesterase inhibitors for autistic spectrum disorders | 2023 | Does not use RoB 2.0 |  |
| Dervenis, P, Dervenis, N, Smith, JM, Steel, DHW | Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy | 2023 | Does not use RoB 2.0 |  |
| Konnyu KJ, Yogasingam S, Lépine J, Sullivan K, Alabousi M, Edwards A, Hillmer M, Karunananthan S, Lavis JN, Linklater S, Manns BJ, Moher D, Mortazhejri S, Nazarali S, Paprica PA, Ramsay T, Ryan PM, Sargious P, Shojania KG, Straus SE, Tonelli M, Tricco A, Vachon B, Yu CH, Zahradnik M, Trikalinos TA, Grimshaw JM, Ivers N | Quality improvement strategies for diabetes care: Effects on outcomes for adults living with diabetes | 2023 | Does not use RoB 2.0 |  |
| Shi, J, Gao, Y, Tian, J, Li, J, Xu, J, Mei, F, Li, Z | Negative pressure wound therapy for treating pressure ulcers | 2023 | Does not use RoB 2.0 |  |
| Trivedi, A, Maheshwari, R, Tarnow-Mordi, WO, Saxena, N | Lactoferrin for the postoperative management of term neonates after gastrointestinal surgery | 2023 | Does not use RoB 2.0 |  |
| Hajizadeh, A, Howes, S, Theodoulou, A, Klemperer, E, Hartmann-Boyce, J, Livingstone-Banks, J, Lindson, N | Antidepressants for smoking cessation | 2023 | Does not use RoB 2.0 |  |
| Tadayon Najafabadi, B, Rayner, DG, Shokraee, K, Shokraie, K, Panahi, P, Rastgou, P, Seirafianpour, F, Momeni Landi, F, Alinia, P, Parnianfard, N, Hemmati, N, Banivaheb, B, Radmanesh, R, Alvand, S, Shahbazi, P, Dehghanbanadaki, H, Shaker, E, Same, K, Mohammadi, E, Malik, A, Srivastava, A, Nejat, P, Tamara, A, Chi, Y, Yuan, Y, Hajizadeh, N, Chan, C, Zhen, J, Tahapary, D, Anderson, L, Apatu, E, Schoonees, A, Naude, CE, Thabane, L, Foroutan, F | Obesity as an independent risk factor for COVID-19 severity and mortality | 2023 | Does not use RoB 2.0 |  |
| Sadler E, Khadjesari Z, Ziemann A, Sheehan KJ, Whitney J, Wilson D, Bakolis I, Sevdalis N, Sandall J, Soukup T, Corbett T, Gonçalves-Bradley DC, Walker DM | Case management for integrated care of older people with frailty in community settings | 2023 | Does not use RoB 2.0 |  |
| Martin, C, Littlewood, SJ, Millett, DT, Doubleday, B, Bearn, D, Worthington, HV, Limones, A | Retention procedures for stabilising tooth position after treatment with orthodontic braces | 2023 | Does not use RoB 2.0 |  |
| Pérez-Amate È, Roqué-Figuls M, Fernández-González M, Giné-Garriga M | Exercise interventions for adults after liver transplantation | 2023 | Does not use RoB 2.0 |  |
| Florez ID, Sierra J, Pérez-Gaxiola G | Balanced crystalloid solutions versus 0.9% saline for treating acute diarrhoea and severe dehydration in children | 2023 | Does not use RoB 2.0 |  |
| Ramanadhan, S, Hansen, K, Henderson, JT, Cohen, MA, Paynter, R, Edelman, A | Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception | 2023 | Does not use RoB 2.0 |  |
| Tamminga, SJ, Emal, LM, Boschman, JS, Levasseur, A, Thota, A, Ruotsalainen, JH, Schelvis, RMC, Nieuwenhuijsen, K, van der Molen, HF | Individual-level interventions for reducing occupational stress in healthcare workers | 2023 | Does not use RoB 2.0 |  |
| Lingappan, K, Neveln, N, Arnold, JL, Fernandes, CJ, Pammi, M | Videolaryngoscopy versus direct laryngoscopy for tracheal intubation in neonates | 2023 | Does not use RoB 2.0 |  |
| Birkinshaw, H, Friedrich, CM, Cole, P, Eccleston, C, Serfaty, M, Stewart, G, White, S, Moore, RA, Phillippo, D, Pincus, T | Antidepressants for pain management in adults with chronic pain: a network meta-analysis | 2023 | Does not use RoB 2.0 |  |
| Molenaar, CJL, van Rooijen, SJ, Fokkenrood, HJP, Roumen, RMH, Janssen, L, Slooter, GD | Prehabilitation versus no prehabilitation to improve functional capacity, reduce postoperative complications and improve quality of life in colorectal cancer surgery | 2023 | Does not use RoB 2.0 |  |
| Coyle, ME, Smith, C, Peat, B | Cephalic version by moxibustion for breech presentation | 2023 | Does not use RoB 2.0 |  |
| Bhardwaj, A, Swe, KM, Sinha, NK | Treatment for osteoporosis in people with beta-thalassaemia | 2023 | Does not use RoB 2.0 |  |
| Greene, MC, Kane, J, Alto, M, Giusto, A, Lovero, K, Stockton, M, McClendon, J, Nicholson, T, Wainberg, ML., Johnson, RM, Tol, WAnton | Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries | 2023 | Does not use RoB 2.0 |  |
| Okwundu, CI, Olowoyeye, A, Uthman, OA, Smith, J, Wiysonge, CS, Bhutani, VK, Fiander, M, Gautham, KS | Transcutaneous bilirubinometry versus total serum bilirubin measurement for newborns | 2023 | Does not use RoB 2.0 |  |
| Stoniute, A, Madhuvrata, P, Still, M, Barron-Millar, E, Nabi, G, Omar, MI | Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults | 2023 | Does not use RoB 2.0 |  |
| Hodgson, KA, Wilkinson, D, De Paoli, AG, Manley, BJ | Nasal high flow therapy for primary respiratory support in preterm infants | 2023 | Does not use RoB 2.0 |  |
| Main, E, Rand, S | Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis | 2023 | Does not use RoB 2.0 |  |
| Gordon, M, Sinopoulou, V, Lakunina, S, Gjuladin-Hellon, T, Bracewell, K, Akobeng, AK | Remote care through telehealth for people with inflammatory bowel disease | 2023 | Does not use RoB 2.0 |  |
| Muhd Helmi, MA, Lai, NM, Van Rostenberghe, H, Ayub, I, Mading, E | Antiseptic solutions for skin preparation during central catheter insertion in neonates | 2023 | Does not use RoB 2.0 |  |
| Aldin, A, Besiroglu, B, Adams, A, Monsef, I, Piechotta, V, Tomlinson, E, Hornbach, C, Dressen, N, Goldkuhle, M, Maisch, P, Dahm, P, Heidenreich, A, Skoetz, N | First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis | 2023 | Does not include any eligible trials |  |
| Jones, KA, Freijah, I, Brennan, SE, McKenzie, JE, Bright, TM, Fiolet, R, Kamitsis, I, Reid, C, Davis, E, Andrews, S, Muzik, M, Segal, L, Herrman, H, Chamberlain, C | Interventions from pregnancy to two years after birth for parents experiencing complex post-traumatic stress disorder and/or with childhood experience of maltreatment | 2023 | Does not include any eligible trials |  |
| Gordon, M, Sinopoulou, V, Ibrahim, U, Abdulshafea, M, Bracewell, K, Akobeng, AK | Patient education interventions for the management of inflammatory bowel disease | 2023 | Does not use RoB 2.0 |  |
| Lane, C, Hogg, E, Karwatowska, LA, French, L, Ranieri, VF, Jesnick, LG D, Roberts, C, Scott, S, Senior, R, Skinner, GCM, Kennedy, EM M | Personalised interventions for subgroups of children with conduct problems | 2023 | Does not use RoB 2.0 |  |
| Imdad, A, Pandit, NG, Zaman, M, Minkoff, NZ, Tanner-Smith, EE, Gomez-Duarte, OG, Acra, S, Nicholson, MR | Fecal transplantation for treatment of inflammatory bowel disease | 2023 | Does not use RoB 2.0 |  |
| Prabhu, AR, Rao, IR, Nagaraju, SP, Rajwar, E, Venkatesh, BT, Nair N, S, Pai, G, Reddy, NP, Suvarna, D | Interventions for dialysis patients with hepatitis C virus (HCV) infection | 2023 | Does not use RoB 2.0 |  |
| Frade, S, O'Neill, S, Greene, D, Nutter, E, Cameron, M | Exercise as adjunctive therapy for systemic lupus erythematosus | 2023 | Does not use RoB 2.0 |  |
| Gaitskell, K, Rogozi≈Ñska, E, Platt, S, Chen, Y, Abd El Aziz, M, Tattersall, A, Morrison, J | Angiogenesis inhibitors for the treatment of epithelial ovarian cancer | 2023 | Does not use RoB 2.0 |  |
| Sayed, S, Ngugi, AK, Nwosu, N, Mutebi, MC, Ochieng, P, Mwenda, AS, Salam, RA | Training health workers in clinical breast examination for early detection of breast cancer in low- and middle-income countries | 2023 | Does not use RoB 2.0 |  |
| Johnson, EE, Mamoulakis, C, Stoniute, A, Omar, MI, Sinha, S | Conservative interventions for managing urinary incontinence after prostate surgery | 2023 | Does not use RoB 2.0 |  |
| Williams, G, Hahn, D, Stephens, JH, Craig, JC, Hodson, EM | Cranberries for preventing urinary tract infections | 2023 | Does not use RoB 2.0 |  |
| Li, M, Li, J, Wang, X, Hui, X, Wang, Q, Xie, S, Yan, P, Tian, J, Li, J, Xie, P, Yang, K, Yao, L | Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism | 2023 | Does not use RoB 2.0 |  |
| Gillies, D, Leach, MJ, Perez Algorta, G | Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents | 2023 | Does not use RoB 2.0 |  |
| Boehlke, C, Joos, L, Coune, B, Becker, C, Meerpohl, JJ, Buroh, S, Hercz, D, Schwarzer, G, Becker, G | Pharmacological interventions for pruritus in adult palliative care patients | 2023 | Does not use RoB 2.0 |  |
| Bresnahan, R, Hill, RA, Wang, J | Perampanel add-on for drug-resistant focal epilepsy | 2023 | Does not use RoB 2.0 |  |
| Wong, C-H, Smith, S, Kansra, S | Digital technology for early identification of exacerbations in people with cystic fibrosis | 2023 | Does not use RoB 2.0 |  |
| Wang, X, Ma, Y, Hui, X, Li, M, Li, J, Tian, J, Wang, Q, Yan, P, Li, J, Xie, P, Yang, K, Yao, L | Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis | 2023 | Does not use RoB 2.0 |  |
| Lee, S, You, C, Kucey, A, Alam, F, Papia, G, Kucey, DS, Forbes, T, Choi, S, Dueck, AD, Kayssi, A | General versus loco-regional anesthesia for endovascular aortic aneurysm repair | 2023 | Does not use RoB 2.0 |  |
| Webster, KE, Dor, A, Galbraith, K, Haj Kassem, L, Harrington-Benton, NA, Judd, O, Kaski, D, Maarsingh, OR, MacKeith, S, Ray, J, Van Vugt, VA, Burton, MJ | Non-pharmacological interventions for prophylaxis of vestibular migraine | 2023 | Does not use RoB 2.0 |  |
| Warnock, L, Gates, A | Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis | 2023 | Does not use RoB 2.0 |  |
| Webster, KE, Dor, A, Galbraith, K, Haj Kassem, L, Harrington-Benton, NA, Judd, O, Kaski, D, Maarsingh, OR, MacKeith, S, Ray, J, Van Vugt, VA, Burton, MJ | Pharmacological interventions for acute attacks of vestibular migraine | 2023 | Does not use RoB 2.0 |  |
| Webster, KE, Dor, A, Galbraith, K, Haj Kassem, L, Harrington-Benton, NA, Judd, O, Kaski, D, Maarsingh, OR, MacKeith, S, Ray, J, Van Vugt, VA, Burton, MJ | Pharmacological interventions for prophylaxis of vestibular migraine | 2023 | Does not use RoB 2.0 |  |
| Bruschettini M, Brattström P, Russo C, Onland W, Davis PG, Soll R | Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity | 2023 | Does not use RoB 2.0 |  |
| Mitra, S, de Boode, WP, Weisz, DE, Shah, PS | Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane Systematic Reviews | 2023 | Does not use RoB 2.0 |  |
| Kinoshita M, Borges do Nascimento IJ, Styrmisdóttir L, Bruschettini M | Systemic opioid regimens for postoperative pain in neonates | 2023 | Does not use RoB 2.0 |  |
| Almeida, MO, Narciso Garcia, A, Menezes Costa, LC, van Tulder, MW, Lin, C-WC, Machado, LAC | The McKenzie method for (sub)acute non-specific low back pain | 2023 | Does not use RoB 2.0 |  |
| Persad, E, Pizarro, AB, Bruschettini, M | Non-opioid analgesics for procedural pain in neonates | 2023 | Does not use RoB 2.0 |  |
| Zhang, L, Mendoza-Sassi, RA, Wainwright, CE, Aregbesola, A, Klassen, TP | Nebulised hypertonic saline solution for acute bronchiolitis in infants | 2023 | Does not use RoB 2.0 |  |
| Cashin, AG, Wand, BM, O'Connell, NE, Lee, H, Rizzo, RRN, Bagg, MK, O'Hagan, E, Maher, CG, Furlan, AD, van Tulder, MW, McAuley, JH | Pharmacological treatments for low back pain in adults: an overview of Cochrane Reviews | 2023 | Does not use RoB 2.0 |  |
| Rittiphairoj, T, Roberti, G, Michelessi, M | Anti-vascular endothelial growth factor for neovascular glaucoma | 2023 | Does not use RoB 2.0 |  |
| Roqué i Figuls M, Giné-Garriga M, Granados Rugeles C, Perrotta C, Vilaró J | Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old | 2023 | Does not use RoB 2.0 |  |
| Glechner A, Wagner G, Mitus JW, Teufer B, Klerings I, Böck N, Grillich L, Berzaczy D, Helbich TH, Gartlehner G | Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk | 2023 | Does not include any eligible trials |  |
| Prakash, R, De Paoli, AG, Davis, PG, Oddie, SJ, McGuire, W | Bubble devices versus other pressure sources for nasal continuous positive airway pressure in preterm infants | 2023 | Does not use RoB 2.0 |  |
| Yoshino, CA, Sidney-Annerstedt, K, Wingfield, T, Kirubi, B, Viney, K, Boccia, D, Atkins, S | Experiences of conditional and unconditional cash transfers intended for improving health outcomes and health service use: a qualitative evidence synthesis | 2023 | Does not use RoB 2.0 |  |
| Imdad, A, Rogner, J, Sherwani, RN, Sidhu, J, Regan, A, Haykal, MR, Tsistinas, O, Smith, A, Chan, XHS, Mayo-Wilson, E, Bhutta, ZA | Zinc supplementation for preventing mortality, morbidity, and growth failure in children aged 6 months to 12 years | 2023 | Does not use RoB 2.0 |  |
| de Vaan, MDT, ten Eikelder, MLG, Jozwiak, M, Palmer, KR, Davies-Tuck, M, Bloemenkamp, KWM, Mol, BWJ, Boulvain, M | Mechanical methods for induction of labour | 2023 | Does not use RoB 2.0 |  |
| Dawson, S, Girling, C-J, Cowap, L, Clark-Carter, D | Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis | 2023 | Does not use RoB 2.0 |  |
| Do, DV, Han, G, Abariga, SA, Sleilati, G, Vedula, SS, Hawkins, BS | Blood pressure control for diabetic retinopathy | 2023 | Does not use RoB 2.0 |  |
| Agnew, H, Kitson, S, Crosbie, EJ | Interventions for weight reduction in obesity to improve survival in women with endometrial cancer | 2023 | Does not use RoB 2.0 |  |
| Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C | Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) | 2023 | Does not use RoB 2.0 |  |
| Mota BS, Bevilacqua JLB, Barrett J, Ricci MD, Munhoz AM, Filassi JR, Baracat EC, Riera R | Skin-sparing mastectomy for the treatment of breast cancer | 2023 | Does not use RoB 2.0 |  |
| Yang, IA, Ferry, OR, Clarke, MS, Sim, EHA, Fong, KM | Inhaled corticosteroids versus placebo for stable chronic obstructive pulmonary disease | 2023 | Does not use RoB 2.0 |  |
| Els, C, Jackson, TD, Hagtvedt, R, Kunyk, D, Sonnenberg, B, Lappi, VG, Straube, S | High-dose opioids for chronic non-cancer pain: an overview of Cochrane Reviews | 2023 | Does not use RoB 2.0 |  |
| Morris, NR, Kermeen, FD, Jones, AW, Lee, JYT, Holland, AE | Exercise-based rehabilitation programmes for pulmonary hypertension | 2023 | Does not use RoB 2.0 |  |
| Martinez-Zapata MJ, Salvador I, Martí-Carvajal AJ, Pijoan JI, Cordero JA, Ponomarev D, Kernohan A, Solà I, Virgili G | Anti-vascular endothelial growth factor for proliferative diabetic retinopathy | 2023 | Does not use RoB 2.0 |  |
| Romantsik, O, Smit, E, Odd, DE, Bruschettini, M | Postnatal phenobarbital for the prevention of intraventricular haemorrhage in preterm infants | 2023 | Does not use RoB 2.0 |  |
| Bort-Martí AR, Rowe FJ, Ruiz Sifre L, Ng SM, Bort-Martí S, Ruiz Garcia V | Botulinum toxin for the treatment of strabismus | 2023 | Does not use RoB 2.0 |  |
| Merner, B, Schonfeld, L, Virgona, A, Lowe, D, Walsh, L, Wardrope, C, Graham-Wisener, L, Xafis, V, Colombo, C, Refahi, N, Bryden, P, Chmielewski, R, Martin, F, Messino, NM, Mussared, A, Smith, L, Biggar, S, Gill, M, Menzies, D, Gaulden, CM, Earnshaw, L, Arnott, L, Poole, N, Ryan, RE, Hill, S | Consumers and health providers views and perceptions of partnering to improve health services design, delivery and evaluation: a co-produced qualitative evidence synthesis | 2023 | Does not use RoB 2.0 |  |
| Fox, T, Gould, S, Princy, N, Rowland, T, Lutje, V, Kuehn, R | Therapeutics for treating mpox in humans | 2023 | Does not use RoB 2.0 |  |
| Webster, KE, Kamo, T, Smith, L, Harrington-Benton, NA, Judd, O, Kaski, D, Maarsingh, OR, MacKeith, S, Ray, J, Van Vugt, VA, Burton, MJ | Non-pharmacological interventions for persistent postural-perceptual dizziness (PPPD) | 2023 | Does not use RoB 2.0 |  |
| Möhler R, Calo S, Renom A, Renom H, Meyer G | Personally tailored activities for improving psychosocial outcomes for people with dementia in long-term care | 2023 | Does not use RoB 2.0 |  |
| Trommer, M, Marnitz, S, Skoetz, N, Rupp, R, Niels, T, Morgenthaler, J, Theurich, S, von Bergwelt-Baildon, M, Baues, C, Baumann, FT | Exercise interventions for adults with cancer receiving radiation therapy alone | 2023 | Does not use RoB 2.0 |  |
| Onland, W, van de Loo, M, Offringa, M, van Kaam, A | Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants | 2023 | Does not use RoB 2.0 |  |
| Park, J, Rittiphairoj, T, Wang, X, E, J-Y, Bicket, AK | Device-modified trabeculectomy for glaucoma | 2023 | Does not use RoB 2.0 |  |
| Woreta, FA, Lindsley, KB, Gharaibeh, A, Ng, SM, Scherer, RW, Goldberg, MF | Medical interventions for traumatic hyphema | 2023 | Does not use RoB 2.0 |  |
| Chen, Y-Y, Liu, A-HS, Nurmatov, U, van Schayck, OCP, Kuo, IC | Antibiotics versus placebo for acute bacterial conjunctivitis | 2023 | Does not include any eligible trials |  |
| Bray, JJH, Warraich, M, Whitfield, MG, Peter, CU, Baral, R, Ahmad, M, Ahmad, S, Abraham, GR, Kirresh, A, Sahibzada, MS, Muzaffar, A, Tomson, J, Lambiase, PD, Captur, G, Banerjee, A, Providencia, R | Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation | 2023 | Does not use RoB 2.0 |  |
| Clemson, L, Stark, S, Pighills, AC, Fairhall, NJ, Lamb, SE, Ali, J, Sherrington, C | Environmental interventions for preventing falls in older people living in the community | 2023 | Does not use RoB 2.0 |  |
| Webster, KE, Harrington-Benton, NA, Judd, O, Kaski, D, Maarsingh, OR, MacKeith, S, Ray, J, Van Vugt, VA, Burton, MJ | Pharmacological interventions for persistent postural-perceptual dizziness (PPPD) | 2023 | Does not use RoB 2.0 |  |
| Kim, S, Kong, JH, Lee, Y, Lee, JY, Kang, TW, Kong, TH, Kim, MH, You, SH | Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer | 2023 | Does not use RoB 2.0 |  |
| Olsen, O, Clausen, JA | Planned hospital birth compared with planned home birth for pregnant women at low risk of complications | 2023 | Does not use RoB 2.0 |  |
| Pappachan, JM, Lahart, IM, Viswanath, AK, Borumandi, F, Sodi, R, Metzendorf, M-I, Bongaerts, B | Parathyroidectomy for adults with primary hyperparathyroidism | 2023 | Does not use RoB 2.0 |  |
| Boulvain, M, Thornton, JG | Induction of labour at or near term for suspected fetal macrosomia | 2023 | Does not use RoB 2.0 |  |
| Traeger, AC, Gilbert, SE, Harris, IA, Maher, CG | Spinal cord stimulation for low back pain | 2023 | Does not use RoB 2.0 |  |
| Laursen DR, Nejstgaard CH, Bjørkedal E, Frost AD, Hansen MR, Paludan-Müller AS, Prosenz J, Werner CP, Hróbjartsson A | Impact of active placebo controls on estimated drug effects in randomised trials: a systematic review of trials with both active placebo and standard placebo | 2023 | Does not use RoB 2.0 |  |
| Fortin PM, Fisher SA, Madgwick KV, Trivella M, Hopewell S, Doree C, Estcourt LJ | Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia | 2023 | Does not use RoB 2.0 |  |
| Searle, HKC, Lewis, SR, Coyle, C, Welch, M, Griffin, XL | Ultrasound and shockwave therapy for acute fractures in adults | 2023 | Does not use RoB 2.0 |  |
| Aslam, AA, Sinha, IP, Southern, KW | Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis | 2023 | Does not use RoB 2.0 |  |
| Kinoshita, M, Stempel, KS, Borges do Nascimento, IJ, Bruschettini, M | Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates | 2023 | Does not use RoB 2.0 |  |
| Raphael, CK, El Hage Chehade, NA, Khabsa, J, Akl, EA, Aouad-Maroun, M, Kaddoum, R | Ultrasound-guided arterial cannulation in the paediatric population | 2023 | Does not use RoB 2.0 |  |
| Thijs, L, Voets, E, Denissen, S, Mehrholz, J, Elsner, B, Lemmens, R, Verheyden, GSAF | Trunk training following stroke | 2023 | Does not use RoB 2.0 |  |
| Gottimukkala, SB, Lobo, L, Gautham, KS, Bolisetty, S, Fiander, M, Schindler, T | Intermittent phototherapy versus continuous phototherapy for neonatal jaundice | 2023 | Does not use RoB 2.0 |  |
| Hahn, D, Hodson, EM, Craig, JC | Interventions for preventing and treating kidney disease in IgA vasculitis | 2023 | Does not use RoB 2.0 |  |
| Webster, KE, Galbraith, K, Lee, A, Harrington-Benton, NA, Judd, O, Kaski, D, Maarsingh, OR, MacKeith, S, Ray, J, Van Vugt, VA, Burton, MJ | Intratympanic gentamicin for Ménière's disease | 2023 | Does not use RoB 2.0 |  |
| Webster, KE, Lee, A, Galbraith, K, Harrington-Benton, NA, Judd, O, Kaski, D, Maarsingh, OR, MacKeith, S, Ray, J, Van Vugt, VA, Westerberg, B, Burton, MJ | Intratympanic corticosteroids for Ménière's disease | 2023 | Does not use RoB 2.0 |  |
| Rocha A, Pinto ACPN, Pachito DV, Drager LF, Lorenzi-Filho G, Atallah ÁN | Pharmacological treatment for central sleep apnoea in adults | 2023 | Does not use RoB 2.0 |  |
| Karjalainen, TV, Lusa, V, Page, MJ, O'Connor, D, Massy-Westropp, N, Peters, SE | Splinting for carpal tunnel syndrome | 2023 | Does not use RoB 2.0 |  |
| Webster, KE, George, B, Lee, A, Galbraith, K, Harrington-Benton, NA, Judd, O, Kaski, D, Maarsingh, OR, MacKeith, S, Murdin, L, Ray, J, Van Vugt, VA, Burton, MJ | Lifestyle and dietary interventions for Ménière's disease | 2023 | Does not use RoB 2.0 |  |
| Lee, A, Webster, KE, George, B, Harrington-Benton, NA, Judd, O, Kaski, D, Maarsingh, OR, MacKeith, S, Ray, J, Van Vugt, VA, Burton, MJ | Surgical interventions for Ménière's disease | 2023 | Does not use RoB 2.0 |  |
| Webster, KE, George, B, Galbraith, K, Harrington-Benton, NA, Judd, O, Kaski, D, Maarsingh, OR, MacKeith, S, Ray, J, Van Vugt, VA, Burton, MJ | Positive pressure therapy for Ménière's disease | 2023 | Does not use RoB 2.0 |  |
| Webster, KE, Galbraith, K, Harrington-Benton, NA, Judd, O, Kaski, D, Maarsingh, OR, MacKeith, S, Ray, J, Van Vugt, VA, Burton, MJ | Systemic pharmacological interventions for Ménière's disease | 2023 | Does not use RoB 2.0 |  |
| Briggs, VR, Jacques, RM, Fotheringham, J, Maheswaran, R, Campbell, M, Wilkie, ME | Catheter insertion techniques for improving catheter function and clinical outcomes in peritoneal dialysis patients | 2023 | Does not use RoB 2.0 |  |
| Perais, J, Agarwal, R, Evans, JR, Loveman, E, Colquitt, JL, Owens, D, Hogg, RE, Lawrenson, JG, Takwoingi, Y, Lois, N | Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy | 2023 | Does not use RoB 2.0 |  |
| Bongioanni, P, Borasio, GD, Oliver, DJ, Romagnoli, A, Kapitza, KP, Sidle, K, Tramonti, F | Methods for informing people with amyotrophic lateral sclerosis/motor neuron disease of their diagnosis | 2023 | Does not use RoB 2.0 |  |
| Lourijsen, E, Avdeeva, K, Gan, KL, Pundir, V, Fokkens, W | Tranexamic acid for the reduction of bleeding during functional endoscopic sinus surgery | 2023 | Does not use RoB 2.0 |  |
| Gordon, M, Wallace, C, Sinopoulou, V, Akobeng, AK | Probiotics for management of functional abdominal pain disorders in children | 2023 | Does not use RoB 2.0 |  |
| Beverly A, Ong G, Kimber C, Sandercock J, Dorée C, Welton NJ, Wicks P, Estcourt LJ | Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and network meta-analysis | 2023 | Does not use RoB 2.0 |  |
| Romantsik O, Moreira A, Thébaud B, Ådén U, Ley D, Bruschettini M | Stem cell-based interventions for the prevention and treatment of intraventricular haemorrhage and encephalopathy of prematurity in preterm infants | 2023 | Does not use RoB 2.0 |  |
| Motuhifonua, SK, Lin, L, Alsweiler, J, Crawford, TJ, Crowther, CA | Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes | 2023 | Does not use RoB 2.0 |  |
| Chung, EYM, Palmer, SC, Saglimbene, VM, Craig, JC, Tonelli, M, Strippoli, GFM | Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis | 2023 | Does not use RoB 2.0 |  |
| Velez M, Lugo-Agudelo LH, Patiño Lugo DF, Glenton C, Posada AM, Mesa Franco LF, Negrini S, Kiekens C, Spir Brunal MA, Roberg AB, Cruz Sarmiento KM | Factors that influence the provision of home-based rehabilitation services for people needing rehabilitation: a qualitative evidence synthesis | 2023 | Does not use RoB 2.0 |  |
| Sanner, JRF, Jain, K, Williams, J, Hurley, MN | Antibiotics for chronic pulmonary infection in children with a neurodisability (neurodevelopmental disorder) | 2023 | Does not use RoB 2.0 |  |
| Barnett, T, Tollit, M, Ratnapalan, S, Sawyer, SM, Kelaher, M | Education support services for improving school engagement and academic performance of children and adolescents with a chronic health condition | 2023 | Does not use RoB 2.0 |  |
| Williamson, A, Martineau, AR, Sheikh, A, Jolliffe, D, Griffiths, CJ | Vitamin D for the management of asthma | 2023 | Does not use RoB 2.0 |  |
| Prior, D, Win, S, Hassiotis, A, Hall, I, Martiello, MA, Ali, AK | Behavioural and cognitive-behavioural interventions for outwardly directed aggressive behaviour in people with intellectual disabilities | 2023 | Does not use RoB 2.0 |  |
| Luo, J, Wang, T, Yang, K, Wang, X, Xu, R, Gong, H, Zhang, X, Wang, J, Yang, R, Gao, P, Ma, Y, Jiao, L | Endovascular therapy versus medical treatment for symptomatic intracranial artery stenosis | 2023 | Does not use RoB 2.0 |  |
| Smith, S, Calthorpe, R, Herbert, S, Smyth, AR | Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis | 2023 | Does not include any eligible trials |  |
| Wilson, LM, Saldanha, IJ, Robinson, KA | Active cycle of breathing technique for cystic fibrosis | 2023 | Does not use RoB 2.0 |  |
| Mulimani, P, Abas, ABL, Karanth, L, Colombatti, R, Kulkarni, P | Treatment of dental and orthodontic complications in thalassaemia | 2023 | Does not use RoB 2.0 |  |
| Ashworth, NL, Bland, JD P, Chapman, KM, Tardif, G, Albarqouni, L, Nagendran, A | Local corticosteroid injection versus placebo for carpal tunnel syndrome | 2023 | Does not use RoB 2.0 |  |
| Adão D, Gois AF, Pacheco RL, Pimentel CF, Riera R | Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage | 2023 | Does not use RoB 2.0 |  |
| Woods, B, Rai, HK, Elliott, E, Aguirre, E, Orrell, M, Spector, A | Cognitive stimulation to improve cognitive functioning in people with dementia | 2023 | Does not use RoB 2.0 |  |
| Lin, JC, Song, S, Ng, SM, Scott, IU, Greenberg, PB | Interventions for acute non-arteritic central retinal artery occlusion | 2023 | Does not include any eligible trials |  |
| Jefferson, T, Dooley, L, Ferroni, E, Al-Ansary, LA, van Driel, ML, Bawazeer, GA, Jones, MA, Hoffmann, TC, Clark, J, Beller, EM, Glasziou, PP, Conly, JM | Physical interventions to interrupt or reduce the spread of respiratory viruses | 2023 | Does not use RoB 2.0 |  |
| Zamora-de La Cruz, D, Bartlett, J, Gutierrez, M, Ng, SM | Trifocal intraocular lenses versus bifocal intraocular lenses after cataract extraction among participants with presbyopia | 2023 | Does not use RoB 2.0 |  |
| Méndez-Sánchez L, Clark P, Winzenberg TM, Tugwell P, Correa-Burrows P, Costello R | Calcium and vitamin D for increasing bone mineral density in premenopausal women | 2023 | Does not use RoB 2.0 |  |
| Kimber, C, Valk, SJ, Chai, KL, Piechotta, V, Iannizzi, C, Monsef, I, Wood, EM, Lamikanra, AA, Roberts, DJ, McQuilten, Z, So-Osman, C, Estcourt, LJ, Skoetz, N | Hyperimmune immunoglobulin for people with COVID-19 | 2023 | Does not include any eligible trials |  |
| Cochrane A, Chen C, Stephen J, Rønning OM, Anderson CS, Hankey GJ, Al-Shahi Salman R | Antithrombotic treatment after stroke due to intracerebral haemorrhage | 2023 | Does not use RoB 2.0 |  |
| Broderick, C, Kobayashi, S, Suto, M, Ito, S, Kobayashi, T | Intravenous immunoglobulin for the treatment of Kawasaki disease | 2023 | Does not use RoB 2.0 |  |
| Grundeis, F, Ansems, K, Dahms, K, Thieme, V, Metzendorf, M-I, Skoetz, N, Benstoem, C, Mikolajewska, A, Griesel, M, Fichtner, F, Stegemann, M | Remdesivir for the treatment of COVID-19 | 2023 | Does not include any eligible trials |  |
| Bauza, V, Ye, W, Liao, J, Majorin, F, Clasen, T | Interventions to improve sanitation for preventing diarrhoea | 2023 | Does not use RoB 2.0 |  |
| Smith, TO, Gaukroger, A, Metcalfe, A, Hing, CB | Surgical versus non-surgical interventions for treating patellar dislocation | 2023 | Does not use RoB 2.0 |  |
| Neligan, A, Adan, G, Nevitt, SJ, Pullen, A, Sander, JW, Bonnett, L, Marson, AG | Prognosis of adults and children following a first unprovoked seizure | 2023 | Does not use RoB 2.0 |  |
| Sandford, A, Haywood, A, Rickett, K, Good, P, Khan, S, Foster, K, Hardy, JR | Corticosteroids for the management of cancer-related fatigue in adults with advanced cancer | 2023 | Does not use RoB 2.0 |  |
| Bülow C, Clausen SS, Lundh A, Christensen M | Medication review in hospitalised patients to reduce morbidity and mortality | 2023 | Does not use RoB 2.0 |  |
| Gorry, C, McCullagh, L, O'Donnell, H, Barrett, S, Schmitz, S, Barry, M, Curtin, K, Beausang, E, Barry, R, Coyne, I | Neoadjuvant treatment for stage III and IV cutaneous melanoma | 2023 | Does not use RoB 2.0 |  |
| Reddy, A, Liu, S-H, Brady, CJ, Sieving, PC, Palestine, AG | Corticosteroid implants for chronic non-infectious uveitis | 2023 | Does not use RoB 2.0 |  |
| Hodson, EM, Cooper, TE | Altered dietary salt intake for preventing diabetic kidney disease and its progression | 2023 | Does not use RoB 2.0 |  |
| Liang, F, Liu, S, Liu, G, Liu, H, Wang, Q, Song, B, Yao, L | Remote ischaemic preconditioning versus no remote ischaemic preconditioning for vascular and endovascular surgical procedures | 2023 | Does not use RoB 2.0 |  |
| Bittner, AK, Yoshinaga, PD, Rittiphairoj, T, Li, T | Telerehabilitation for people with low vision | 2023 | Does not include any eligible trials |  |
| Agabio R, Saulle R, Rösner S, Minozzi S | Baclofen for alcohol use disorder | 2023 | Does not use RoB 2.0 |  |
| Foong, WC, Loh, CK, Ho, JJ, Lau, DSC | Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias | 2023 | Does not use RoB 2.0 |  |
| Das, RR, Singh, M, Naik, SS | Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia | 2023 | Does not use RoB 2.0 |  |
| Jassim, GA, Doherty, S, Whitford, DL, Khashan, AS | Psychological interventions for women with non-metastatic breast cancer | 2023 | Does not use RoB 2.0 |  |
| Wang, Q, Wu, J, Ma, Y, Zhu, Y, Song, X, Xie, S, Liang, F, Gimzewska, M, Li, M, Yao, L | Totally percutaneous versus surgical cut-down femoral artery access for elective bifurcated abdominal endovascular aneurysm repair | 2023 | Does not use RoB 2.0 |  |
| Aregbesola, A, Tam, CM, Kothari, A, Le, M-L, Ragheb, M, Klassen, TP | Glucocorticoids for croup in children | 2023 | Does not use RoB 2.0 |  |
| Liu, J, Wang, L-N | Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack | 2023 | Does not use RoB 2.0 |  |
| Murphy, DJ, Devane, D, Molloy, E, Shahabuddin, Y | Fetal scalp stimulation for assessing fetal well-being during labour | 2023 | Does not use RoB 2.0 |  |
| Jeffery, TC, Chang, AB, Conwell, LS | Bisphosphonates for osteoporosis in people with cystic fibrosis | 2023 | Does not use RoB 2.0 |  |
| Rouse, B, Le, JT, Gazzard, G | Iridotomy to slow progression of visual field loss in angle-closure glaucoma | 2023 | Does not use RoB 2.0 |  |
| de Moraes Silva, MA, Nakano, LCU, Cisneros, LL, Miranda Jr, F | Balneotherapy for chronic venous insufficiency | 2023 | Does not use RoB 2.0 |  |
| Wilfling D, Calo S, Dichter MN, Meyer G, Möhler R, Köpke S | Non-pharmacological interventions for sleep disturbances in people with dementia | 2023 | Does not use RoB 2.0 |  |
| Jiang, S, Fang, J, Li, W | Protein restriction for diabetic kidney disease | 2023 | Does not use RoB 2.0 |  |
| Tian, F, Jiang, Q, Chen, J, Liu, Z | Silicone gel sheeting for treating keloid scars | 2023 | Does not use RoB 2.0 |  |
| Jasani B, Mitra S, Shah PS | Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants | 2022 | Does not use RoB 2.0 |  |
| Wingert AM, Liu SH, Lin JC, Sridhar J | Non-steroidal anti-inflammatory agents for treating cystoid macular edema following cataract surgery | 2022 | Does not use RoB 2.0 |  |
| Onland W, Offringa M, van Kaam A | Late (>= 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants | 2022 | Does not use RoB 2.0 |  |
| Montesinos-Guevara C, Buitrago-Garcia D, Felix ML, Guerra CV, Hidalgo R, Martinez-Zapata MJ, Simancas-Racines D | Vaccines for the common cold | 2022 | Does not use RoB 2.0 |  |
| Hawke K, King D, van Driel ML, McGuire TM | Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children | 2022 | Does not use RoB 2.0 |  |
| Lo DKH, Muhlebach MS, Smyth AR | Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis | 2022 | Does not use RoB 2.0 |  |
| Strobel NA, Chamberlain C, Campbell SK, Shields L, Bainbridge RG, Adams C, Edmond KM, Marriott R, McCalman J | Family‐centred interventions for Indigenous early childhood well‐being by primary healthcare services | 2022 | Does not use RoB 2.0 |  |
| Mergoni G, Ganim M, Lodi G, Figini L, Gagliani M, Manfredi M | Single versus multiple visits for endodontic treatment of permanent teeth | 2022 | Does not use RoB 2.0 |  |
| Tada M, Yamada N, Matsumoto T, Takeda C, Furukawa TA, Watanabe N | Ultrasound guidance versus landmark method for peripheral venous cannulation in adults | 2022 | Does not use RoB 2.0 |  |
| Gokulakrishnan G, Kulkarni M, He S, Leeflang MGM, Cabrera AG, Fernandes CJ, Pammi M | Brain natriuretic peptide and N‐terminal brain natriuretic peptide for the diagnosis of haemodynamically significant patent ductus arteriosus in preterm neonates | 2022 | Does not use RoB 2.0 |  |
| Myint KT, Sahoo S, Thein AW, Moe S, Ni H | Laser therapy for retinopathy in sickle cell disease | 2022 | Does not use RoB 2.0 |  |
| Midya S, Ghosh D, Mahmalat MW | Fundoplication in laparoscopic Heller's cardiomyotomy for achalasia | 2022 | Does not use RoB 2.0 |  |
| Thomson SE, Ng NYB, Riehle MO, Kingham PJ, Dahlin LB, Wiberg M, Hart AM | Bioengineered nerve conduits and wraps for peripheral nerve repair of the upper limb | 2022 | Does not use RoB 2.0 |  |
| Campbell ZC, Dawson JK, Kirkendall SM, McCa ery KJ, Jansen J, Campbell KL, Lee VWS, Webster AC | Interventions for improving health literacy in people with chronic kidney disease | 2022 | Does not use RoB 2.0 |  |
| Nishioka N, Luo Y, Taniguchi T, Ohnishi T, Kimachi M, Ng RCK, Watanabe N | Carnitine supplements for people with chronic kidney disease requiring dialysis | 2022 | Does not use RoB 2.0 |  |
| Knight-Madden JM, Hambleton IR | Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease | 2022 | Does not use RoB 2.0 |  |
| Abdel-Aleem H, Shaaban OM, Abdel-Aleem MA, Aboelfadle Mohamed A | Cervical pessary for preventing preterm birth in singleton pregnancies | 2022 | Does not use RoB 2.0 |  |
| Kotani Y, Kataoka Y, Izawa J, Fujioka S, Yoshida T, Kumasawa J, Kwong JSW | High versus low blood pressure targets for cardiac surgery while on cardiopulmonary bypass | 2022 | Does not use RoB 2.0 |  |
| Chin B, Wee I, Syn NLX, O'Neill GK, Yap ES, Koh PL | Surgery for chronic arthropathy in people with haemophilia | 2022 | Does not use RoB 2.0 |  |
| Pilkington K, Wieland LS, Teng L, Jin XY, Storey D, Liu JP | Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer. | 2022 | Does not use RoB 2.0 |  |
| Uneno Y, Imura H, Makuuchi Y, Tochitani K, Watanabe N | Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer | 2022 | Does not use RoB 2.0 |  |
| Kirkman MA, Day J, Gehring K, Zienius K, Grosshans D, Taphoorn M, Li J, Brown PD | Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation | 2022 | Does not use RoB 2.0 |  |
| Kuehn R, Stoesser N, Eyre D, Darton TC, Basnyat B, Parry CM | Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins | 2022 | Does not use RoB 2.0 |  |
| Vlajkovic T, Grigore M, van Eekelen R, Puscasiu L | Day 5 versus day 3 embryo biopsy for preimplantation genetic testing for monogenic/single gene defects | 2022 | Does not use RoB 2.0 |  |
| Fayad AI, Buamscha DG, Ciapponi A | Timing of kidney replacement therapy initiation for acute kidney injury. | 2022 | Does not use RoB 2.0 |  |
| Amaral FCF, Baptista-Silva JCC, Nakano LCU, Flumignan RLG | Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery | 2022 | Does not use RoB 2.0 |  |
| Georgiou EX, Melo P, Cheong YC, Granne IE | Follicular flushing during oocyte retrieval in assisted reproductive techniques | 2022 | Does not use RoB 2.0 |  |
| Hayes | Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding | 2022 | Does not use RoB 2.0 |  |
| Muqit MMK, Mehat M, Bunce C, Bainbridge JW | Early vitrectomy for exogenous endophthalmitis following surgery | 2022 | Does not use RoB 2.0 |  |
| Saiz LC, Gorricho J, Garjón J, Celaya MC, Erviti J, Leache L | Blood pressure targets for the treatment of people with hypertension and cardiovascular disease | 2022 | Does not use RoB 2.0 |  |
| Wieland LS, Skoetz N, Pilkington K, Harbin S, Vempati R, Berman BM | Yoga for chronic non‐specific low back pain | 2022 | Does not use RoB 2.0 |  |
| Hartmann-Boyce J, Lindson N, Butler AR, McRobbie H, Bullen C, Begh R, Theodoulou A, Notley C, Rigotti NA, Turner T, Fanshawe TR, Hajek P | Electronic cigarettes for smoking cessation | 2022 | Does not use RoB 2.0 |  |
| Allida S, House A, Hackett ML | Pharmaceutical interventions for emotionalism after stroke | 2022 | Does not use RoB 2.0 |  |
| Fox T, Geppert J, Dinnes J, Scandrett K, Bigio J, Sulis G, Hettiarachchi D, Mathangasinghe Y, Weeratunga P, Wickramasinghe D, Bergman H, Buckley BS, Probyn K, Sguassero Y, Davenport C, Cunningham J, Dittrich S, Emperador D, Hoo, L, Leeflang MMG, McInnes MDF, Spijker R, Struyf T, Van den Bruel A, Verbakel JY, Takwoingi Y, Taylor-Phillips S, Deeks JJ, Cochrane COVID-19 Diagnostic Test Accuracy Group | Antibody tests for identification of current and past infection with SARS‐CoV‐2 | 2022 | Does not use RoB 2.0 |  |
| Dower A, Mulcahy M, Maharaj M, Chen H, Lim CED, Li Y, Sheridan M | Surgical decompression for malignant cerebral oedema after ischaemic stroke | 2022 | Does not use RoB 2.0 |  |
| Cao Y, Liu C, Lin J, Ng L, Needleman I, Walsh T, Li C | Oral care measures for preventing nursing home‐acquired pneumonia | 2022 | Does not use RoB 2.0 |  |
| Sereda M, Xia J, Scutt P, Hilton MP, El Refaie A, Hoare DJ | Ginkgo biloba for tinnitus | 2022 | Does not use RoB 2.0 |  |
| Smith S, Rowbotham NJ | Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis | 2022 | Does not use RoB 2.0 |  |
| Kelleher MM, Phillips R, Brown SJ, Cro S, Cornelius V, Carlsen KCL, Skjerven HO, Rehbinder EM, Lowe AJ, Dissanayake E, Shimojo N, Yonezawa K, Ohya Y, Yamamoto-Hanada K, Morita K, Axon E, Cork M, Cooke A, Van Vogt E, Schmitt J, Weidinger S, McClanahan D, Simpson E, Duley L, Askie LM, Williams HC, Boyle RJ | Skin care interventions in infants for preventing eczema and food allergy | 2022 | Does not include any eligible trials |  |
| Ballout RA, Livinski A, Fu YP, Steiner RD, Remaley AT | Statins for Smith‐Lemli‐Opitz syndrome | 2022 | Does not use RoB 2.0 |  |
| Prakash R, De Paoli AG, Oddie SJ, Davis PG, McGuire W | Masks versus prongs as interfaces for nasal continuous positive airway pressure in preterm infants | 2022 | Does not use RoB 2.0 |  |
| Fraser A, Poole P | Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease | 2022 | Does not use RoB 2.0 |  |
| Stoffers-Winterling | Pharmacological interventions for people with borderline personality disorder | 2022 | Does not use RoB 2.0 |  |
| Aoki Y, Yaju Y, Utsumi T, Sanyaolu L, Storm M, Takaesu Y, Watanabe K, Watanabe N, Duncan E, Edwards AGK | Shared decision‐making interventions for people with mental health conditions | 2022 | Does not use RoB 2.0 |  |
| Backe P, Bruschettini M, Sibrecht G, Thernstrom Blomqvist Y, Olsson E | Pharmacological interventions for pain and sedation management in newborn infants undergoing therapeutic hypothermia | 2022 | Does not use RoB 2.0 |  |
| Germans | Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage | 2022 | Does not use RoB 2.0 |  |
| Hazelton C, Thomson K, Todhunter-Brown A, Campbell P, Chung CSY, Dorris L, Gillespie DC, Hunter SM, McGill K, Nicolson DJ, Williams LJ, Brady MC | Interventions for perceptual disorders following stroke | 2022 | Does not use RoB 2.0 |  |
| Sothornwit J, Kaewrudee S, Lumbiganon P, Pattanittum P, Averbach SH | Immediate versus delayed postpartum insertion of contraceptive implant and IUD for contraception | 2022 | Does not use RoB 2.0 |  |
| Gavine A, Shinwell SC, Buchanan P, Farre A, Wade A, Lynn F, Marshall J, Cumming SE, Dare S, McFadden A | Support for healthy breastfeeding mothers with healthy term babies | 2022 | Does not use RoB 2.0 |  |
| Pinto ACPN, Rocha A, Drager LF, Lorenzi-Filho G, Pachito DV | Non‐invasive positive pressure ventilation for central sleep apnoea in adults | 2022 | Does not use RoB 2.0 |  |
| Bui BN, Lensen SF, Gibreel A, Martins WP, Torrance H, Broekmans FJ | Endometrial injury for pregnancy following sexual intercourse or intrauterine insemination | 2022 | Does not use RoB 2.0 |  |
| Chou R, Pinto RZ, Fu R, Lowe RA, Henschke N, McAuley JH, Dana T | Systemic corticosteroids for radicular and non‐radicular low back pain | 2022 | Does not use RoB 2.0 |  |
| Leaney AA, Lyttle JR, Segan J, Urquhart DM, Cicuttini FM, Chou L, Wluka AE | Antidepressants for hip and knee osteoarthritis | 2022 | Does not use RoB 2.0 |  |
| Smedemark SA, Aabenhus R, Llor C, Fournaise A, Olsen O, Jørgensen KJ | Biomarkers as point‐of‐care tests to guide prescription of antibiotics in people with acute respiratory infections in primary care | 2022 | Does not use RoB 2.0 |  |
| Karrim N, Byrne R, Magula N, Saman Y | Antihistamines for motion sickness | 2022 | Does not use RoB 2.0 |  |
| Renton WD, Jung J, Palestine AG | Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis  | 2022 | Does not include any eligible trials |  |
| French HP, Abbott JH, Galvin R | Adjunctive therapies in addition to land‐based exercise therapy for osteoarthritis of the hip or knee | 2022 | Does not use RoB 2.0 |  |
| Norman G, Wong JKF, Amin K, Dumville JC, Pramod S | Reconstructive surgery for treating pressure ulcers | 2022 | Does not use RoB 2.0 |  |
| Silva JAM, Mininel VA, Fernandes Agreli H, Peduzzi M, Harrison R, Xyrichis A | Collective leadership to improve professional practice, healthcare outcomes and staff well‐being | 2022 | Does not use RoB 2.0 |  |
| Dwan K, Kirkham J, Paton RW, Morley E, Newton AW, Perry DC | Splinting for the non‐operative management of developmental dysplasia of the hip (DDH) in children under six months of age | 2022 | Does not use RoB 2.0 |  |
| Craciunas L, Zdoukopoulos N, Vinayagam S, Mohiyiddeen L | Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency | 2022 | Does not use RoB 2.0 |  |
| Claireaux HA, Searle HKC, Parsons NR, Gri!in XL | Interventions for treating fractures of the distal femur in adults | 2022 | Does not use RoB 2.0 |  |
| Brown SJ, Carter GJ, Halliwell G, Brown K, Caswell R, Howarth E, Feder G, O'Doherty L | Survivor, family and professional experiences of psychosocial interventions for sexual abuse and violence: a qualitative evidence synthesis | 2022 | Does not use RoB 2.0 |  |
| Ye Z, Cao Y, Miao C, Liu W, Dong L, Lv Z, Iheozor-Ejiofor Z, Li C | Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis | 2022 | Does not use RoB 2.0 |  |
| Nantakool S, Reanpang T, Prasannarong M, Pongtam S, Rerkasem K | Upper limb exercise for arteriovenous fistula maturation in people requiring permanent haemodialysis access | 2022 | Does not use RoB 2.0 |  |
| Agarwal SM, Stogios N, Ahsan ZA, Lockwood JT, Duncan MJ, Takeuchi H, Cohn T, Taylor VH, Remington G, Faulkner GEJ, Hahn M | Pharmacological interventions for prevention of weight gain in people with schizophrenia | 2022 | Does not use RoB 2.0 |  |
| Brignell A, Harwood RC, May T, Woolfenden S, Montgomery A, Iorio A, Williams K | Overall prognosis of preschool autism spectrum disorder diagnoses | 2022 | Does not use RoB 2.0 |  |
| Kamo T, Wada Y, Okamura M, Sakai K, Momosaki R, Taito S | Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke | 2022 | Does not use RoB 2.0 |  |
| Granger C, Cavalheri V | Preoperative exercise training for people with non‐small cell lung cancer | 2022 | Does not use RoB 2.0 |  |
| de Baat EC, Mulder RL, Armenian S, Feijen EAM, Grotenhuis H, Hudson MM, MavinkurveGroothuis AMC, Kremer LCM, van Dalen EC | Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines | 2022 | Does not use RoB 2.0 |  |
| Franik S, Le QK, Kremer JAM, Kiesel L, Farquhar C | Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome | 2022 | Does not use RoB 2.0 |  |
| Buder K, Zirngibl M, Bapistella S, Meerpohl JJ, Strahm B, Bassler D, Weitz M | Extracorporeal photopheresis versus standard treatment for acute graft‐versus‐host disease after haematopoietic stem cell transplantation in children and adolescents | 2022 | Does not use RoB 2.0 |  |
| Daly BJM, Sharif MO, Jones K, Worthington HV, Beattie A | Local interventions for the management of alveolar osteitis (dry socket) | 2022 | Does not use RoB 2.0 |  |
| Leszczynski R, da Silva CAP, Pinto ACPN, Kuczynski U, da Silva EMK | Laser therapy for treating hypertrophic and keloid scars | 2022 | Does not use RoB 2.0 |  |
| Monk-Cunlie J, Borschmann R, Monk A, O'Mahoney J, Henderson C, Phillips R, Gibb J, Moran P | Crisis interventions for adults with borderline personality disorder | 2022 | Does not use RoB 2.0 |  |
| Bryant A, Hiu S, Kunonga PT, Gajjar K, Craig D, Vale L, Winter-Roach BA, Elattar A, Naik R | Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery | 2022 | Does not use RoB 2.0 |  |
| Hargreaves E, Baker K, Barry G, Harding C, Zhang Y, Kandala NB, Zhang X, Kernohan A, Clarkson CE | Acupuncture for treating overactive bladder in adults | 2022 | Does not use RoB 2.0 |  |
| McTavish D, Thornton J | Appetite stimulants for people with cystic fibrosis | 2022 | Does not use RoB 2.0 |  |
| Dowling N, Merkouris S, Lubman D, Thomas S, Bowden-Jones H, Cowlishaw S | Pharmacological interventions for the treatment of disordered and problem gambling | 2022 | Does not use RoB 2.0 |  |
| Reis S, Metzendorf MI, Kuehn R, Popp M, Gagyor I, Kranke P, Meybohm P, Skoetz N, Weibel S | Nirmatrelvir combined with ritonavir for preventing and treating COVID-19 | 2022 | Does not include any eligible trials |  |
| Cooper TE, Scholes-Robertson N, Craig JC, Hawley CM, Howell M, Johnson DW, Teixeira-Pinto A, Jaure A, Wong G | Synbiotics, prebiotics and probiotics for solid organ transplant recipients | 2022 | Does not use RoB 2.0 |  |
| Chakrabarti M, Nordin A, Khodabocus J | Debulking hysterectomy followed by chemoradiotherapy versus chemoradiotherapy for FIGO stage (2019) IB3/II cervical cancer | 2022 | Does not use RoB 2.0 |  |
| Candy B, Jones L, Vickersta‑ V, Larkin PJ, Stone P | Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care | 2022 | Does not use RoB 2.0 |  |
| Singh R, Barker L, Chen SI, Shah A, Long V, Dahlmann-Noor A | Surgical interventions for bilateral congenital cataract in children aged two years and under | 2022 | Does not use RoB 2.0 |  |
| Fernandez R, Green HL, Griiths R, Atkinson RA, Ellwood LJ | Water for wound cleansing | 2022 | Does not use RoB 2.0 |  |
| Day J, Yust-Katz S, Cachia D, Wefel J, Tremont Lukats IW, Bulbeck H, Rooney AG | Interventions for the management of fatigue in adults with a primary brain tumour | 2022 | Does not use RoB 2.0 |  |
| Mellon L, Doyle F, Hickey A, Ward KD, de Freitas DG, McCormick PA, O'Connell O, Conlon P | Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients | 2022 | Does not use RoB 2.0 |  |
| Kramer A, Prinz C, Fichtner F, Fischer AL, Thieme V, Grundeis F, Spagl M, Seeber C, Piechotta V, Metzendorf MI, Golinski M, Moerer O, Stephani C, Mikolajewska A, Kluge S, Stegemann M, Laudi S, Skoetz N | Janus kinase inhibitors for the treatment of COVID‐19 | 2022 | Does not include any eligible trials |  |

# Supplement 4: Weighted kappa values for trials addressing pharmacologic treatments

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Category | Optimized | 95% CI | Minimal | 95% CI | Maximal | 95% CI |
| Overall | 0.09 | -0.09 - 0.28 | 0.08 | -0.08 - 0.24 | 0.06 | -0.09 - 0.22 |
| Risk of bias due to randomization | 0.30 | 0.05 - 0.55 | 0.05 | -0.22 - 0.31 | 0.06 | -0.21 - 0.32 |
| Risk of bias due to deviations from the intended intervention | 0.21 | -0.04 - 0.46 | 0.16 | -0.10 - 0.42 | 0.07 | -0.19 - 0.34 |
| Risk of bias due to missing outcome data | 0.18 | -0.01 - 0.37 | 0.14 | -0.08 - 0.36 | 0.06 | -0.20 - 0.33 |
| Risk of bias due to measurement of the outcome | -0.004 | -0.23 - 0.23 | 0.05 | -0.26 - 0.36 | -0.07 | -0.31 - 0.17 |
| Risk of bias due to selective reporting | 0.17 | -0.04 - 0.37 | 0.29 | 0.05 - 0.54 | 0.13 | -0.05 - 0.31 |

# Supplement 5: Weighted kappa values for trials from reviews that assessed the risk of bias of assignment to the intervention

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Category | Optimized | 95% CI | Minimal | 95% CI | Maximal | 95% CI |
| Overall | 0.13 | -0.05 - 0.30 | 0.10 | -0.06 - 0.25 | 0.14 | -0.01 - 0.30 |
| Risk of bias due to randomization | 0.24 | 0.00 - 0.47 | 0.12 | -0.09 - 0.34 | 0.11 | -0.15 - 0.36 |
| Risk of bias due to deviations from the intended intervention | 0.07 | -0.16 - 0.31 | 0.01 | -0.21 - 0.22 | 0.07 | -0.19 - 0.33 |
| Risk of bias due to missing outcome data | 0.31 | 0.15 - 0.48 | 0.16 | -0.05 - 0.37 | 0.12 | -0.08 - 0.33 |
| Risk of bias due to measurement of the outcome | 0.16 | -0.13 - 0.44 | 0.05 | -0.18 - 0.28 | 0.03 | -0.21 - 0.27 |
| Risk of bias due to selective reporting | 0.20 | -0.02 - 0.41 | 0.21 | -0.02 - 0.44 | 0.25 | 0.06 - 0.44 |

# Supplement 6: Weighted kappa values for outcomes rated as definitely objective

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Category | Optimized | 95% CI | Minimal | 95% CI | Maximal | 95% CI |
| Overall | 0.16 | -0.02 - 0.35 | 0.11 | -0.09 - 0.32 | 0.09 | -0.06 - 0.24 |
| Risk of bias due to randomization | 0.20 | -0.03 - 0.43 | 0.15 | -0.14 - 0.44 | 0.09 | -0.17 - 0.35 |
| Risk of bias due to deviations from the intended intervention | 0.14 | -0.10 - 0.37 | 0.08 | -0.21 - 0.37 | 0.05 | -0.21 - 0.32 |
| Risk of bias due to missing outcome data | 0.25 | 0.01 - 0.50 | 0.14 | -0.17 - 0.44 | 0.09 | -0.10 - 0.28 |
| Risk of bias due to measurement of the outcome | -0.11 | -0.33 - 0.11 | 0.03 | -0.25 - 0.30 | 0.24 | -0.07 - 0.56 |
| Risk of bias due to selective reporting | 0.15 | -0.06 - 0.37 | 0.21 | -0.04 - 0.46 | 0.13 | -0.04 - 0.31 |

# Supplement 7: Weighted kappa values for outcomes rated as definitely subjective

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Category | Optimized | 95% CI | Minimal | 95% CI | Maximal | 95% CI |
| Overall | 0.19 | -0.06 - 0.45 | 0.12 | -0.14 - 0.38 | 0.12 | -0.06 - 0.31 |
| Risk of bias due to randomization | 0.25 | -0.23 - 0.73 | 0.24 | -0.17 - 0.64 | 0.40 | 0.02 - 0.79 |
| Risk of bias due to deviations from the intended intervention | 0.16 | -0.32 - 0.63 | 0.16 | -0.25 - 0.56 | 0.17 | -0.21 - 0.56 |
| Risk of bias due to missing outcome data | 0.48 | 0.28 - 0.68 | 0.38 | 0.06 - 0.71 | 0.19 | -0.18 - 0.55 |
| Risk of bias due to measurement of the outcome | 0.56 | 0.26 - 0.86 | 0.06 | -0.25 - 0.38 | 0.19 | -0.12 - 0.51 |
| Risk of bias due to selective reporting | 0.20 | -0.21 - 0.61 | 0.12 | -0.32 - 0.55 | 0.34 | -0.04 - 0.72 |

# Supplement 8: Weighted kappa values for outcomes rated as definitely objective or as probably objective

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Category | Optimized | 95% CI | Minimal | 95% CI | Maximal | 95% CI |
| Overall | 0.13 | -0.02 - 0.28 | 0.10 | -0.04 - 0.23 | 0.09 | -0.04 - 0.22 |
| Risk of bias due to randomization | 0.17 | -0.03 - 0.37 | 0.07 | -0.16 - 0.29 | -0.02 | -0.23 - 0.19 |
| Risk of bias due to deviations from the intended intervention | 0.17 | -0.03 - 0.36 | 0.12 | -0.11 - 0.35 | 0.06 | -0.15 - 0.27 |
| Risk of bias due to missing outcome data | 0.19 | 0.01 - 0.38 | 0.15 | -0.08 - 0.37 | 0.08 | -0.09 - 0.25 |
| Risk of bias due to measurement of the outcome | -0.18 | -0.31 - -0.06 | 0.03 | -0.21 - 0.27 | 0.18 | -0.11 - 0.47 |
| Risk of bias due to selective reporting | 0.20 | 0.01 - 0.40 | 0.31 | 0.12 - 0.50 | 0.11 | -0.06 - 0.27 |

# Supplement 9: Weighted kappa values for outcomes rated as definitely subjective or as probably subjective

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Category | Optimized | 95% CI | Minimal | 95% CI | Maximal | 95% CI |
| Overall | 0.06 | -0.17 - 0.29 | 0.12 | -0.09 - 0.33 | 0.19 | -0.01 - 0.39 |
| Risk of bias due to randomization | 0.21 | -0.13 - 0.55 | 0.14 | -0.16 - 0.45 | 0.16 | -0.16 - 0.48 |
| Risk of bias due to deviations from the intended intervention | 0.04 | -0.30 - 0.38 | 0.11 | -0.20 - 0.41 | 0.16 | -0.16 - 0.48 |
| Risk of bias due to missing outcome data | 0.34 | 0.15 - 0.53 | 0.31 | 0.03 - 0.58 | 0.17 | -0.11 - 0.46 |
| Risk of bias due to measurement of the outcome | 0.30 | -0.03 - 0.63 | 0.05 | -0.21 - 0.31 | 0.08 | -0.20 - 0.36 |
| Risk of bias due to selective reporting | 0.27 | 0.00 - 0.54 | 0.20 | -0.10 - 0.50 | 0.28 | 0.07 - 0.49 |

# Supplement 10: Weighted kappa values for continuous outcomes

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Category | Optimized | 95% CI | Minimal | 95% CI | Maximal | 95% CI |
| Overall | 0.18 | -0.03 - 0.39 | 0.04 | -0.24 - 0.33 | 0.22 | 0.01 - 0.43 |
| Risk of bias due to randomization | 0.24 | -0.09 - 0.56 | 0.10 | -0.19 - 0.39 | 0.10 | -0.27 - 0.46 |
| Risk of bias due to deviations from the intended intervention | 0.06 | -0.27 - 0.39 | 0.11 | -0.17 - 0.40 | 0.13 | -0.23 - 0.50 |
| Risk of bias due to missing outcome data | 0.27 | 0.07 - 0.47 | 0.10 | -0.17 - 0.37 | 0.10 | -0.16 - 0.36 |
| Risk of bias due to measurement of the outcome | 0.29 | -0.02 - 0.60 | 0.09 | -0.19 - 0.37 | 0.20 | -0.13 - 0.53 |
| Risk of bias due to selective reporting | 0.26 | -0.02 - 0.54 | 0.27 | -0.02 - 0.55 | 0.22 | -0.03 - 0.48 |

# Supplement 11: Weighted kappa values for continuous outcomes

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Category | Optimized | 95% CI | Minimal | 95% CI | Maximal | 95% CI |
| Overall | 0.1 | -0.06 - 0.25 | 0.06 | -0.08 - 0.2 | 0.07 | -0.02 - 0.17 |
| Risk of bias due to randomization | 0.2 | 0 - 0.4 | 0.07 | -0.13 - 0.27 | 0.07 | -0.12 - 0.27 |
| Risk of bias due to deviations from the intended intervention | 0.1 | -0.1 - 0.29 | 0.13 | -0.07 - 0.32 | 0.09 | -0.11 - 0.28 |
| Risk of bias due to missing outcome data | 0.23 | 0.09 - 0.38 | 0.2 | 0.04 - 0.36 | 0.13 | -0.04 - 0.29 |
| Risk of bias due to measurement of the outcome | 0.05 | -0.15 - 0.25 | 0.03 | -0.2 - 0.25 | 0.01 | -0.2 - 0.21 |
| Risk of bias due to selective reporting | 0.14 | -0.05 - 0.33 | 0.28 | 0.09 - 0.47 | 0.2 | 0.05 - 0.36 |

# Supplement 12: Qualitative findings on discrepant risk of bias judgments between Cochrane systematic reviewers and ChatGPT

For all risk of bias judgments, our prompts queried ChatGPT to provide a justification for its rating of risk of bias. To understand reasons why ChatGPT may produce unreliable risk of bias judgments, we also qualitatively reviewed justifications provided by the optimized ChatGPT prompt to support its judgments for potential errors or problems. An analysis of the justifications provided by ChatGPT suggests four major types of problems.

First, it appears that ChatGPT could not distinguish between characteristics of trials that are at low risk of bias and characteristics at high risk of bias. For example, one trial reported randomization by an “interactive web-response system”, which suggests central randomization and allocation concealment (38). The ChatGPT optimized prompt rates the trial at some concerns for randomization because the trial report “does not explicitly mention whether the allocation sequence was concealed”. One trial reported using “system-generated random numbers” to randomize participants (39). The ChatGPT prompt rated risk of bias due to randomization at low risk of bias with the justification that “an open list of random numbers for concealment” indicates “proper randomization process”—an incorrect statement since an open list allows those recruiting participants in a trial to predict the arm to which subsequent participants will be randomized.

Second, ChatGPT was unable to make reasonable assumptions about risk of bias. Cochrane systematic reviewers rated a trial investigating the effects of convalescent plasma on all-cause mortality in COVID-19 patients at low risk of bias for missing outcome data (40). ChatGPT rated the trial at some concerns because it “does not provide explicit details about the availability of outcome data for all participants or if there was significant dropout of participants”. The trial however reports that no patients were lost to follow-up and it is reasonable to assume that all-cause mortality would be one of the outcomes for which there would be no missing outcome data without loss to follow-up since it does not involve active measurement or monitoring by investigators.

Third, ChatGPT made errors that suggested that it was unfamiliar with recommended processes for risk of bias assessments. For example, for the domain bias due to deviations from the intended intervention an open-label trial of aspirin for COVID-19 was judged at high risk of bias by systematic reviewers and low risk of bias by ChatGPT because the outcome ‘all-cause mortality’ is objective (41). While the outcome is objective, the domain of bias due to deviations from intended intervention is meant to solely assess risk of bias due to imbalances in cointerventions or differences in how the intervention is implemented rather than objectivity of the outcome, which is assessed by the bias due to measurement of the outcome domain. Similarly, in making judgments about risk of bias due to selective reporting, ChatGPT often considered discrepancies between all outcomes and results between the trial publication or the registration or protocol instead of the results for which risk of bias was being assessed. Although bias due to randomization should be consistent across outcomes from the same trial, we identified instances in which ChatGPT rated the domain inconsistently across outcomes from the same trial.

Finally, ChatGPT made random errors in assessing risk of bias. For example, in another trial described as double-blind and rated at low risk of bias due to deviations from intended intervention by systematic reviewers, ChatGPT rated risk of bias as high because the trial “does not provide information on whether participants and personnel were aware of the intervention” (42).